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Chapter 1
Introduction
1.1 Molecular basis of protein conformational diseases
1.1.1 Conformational diseases
Conformational diseases, also termed misfolding diseases, are associated with aberrant
protein metabolism in terms of the aggregation and extracellular deposition of otherwise
soluble proteins (Sunde and Blake 1998, Chiti and Dobson 2006). In these conditions
amyloidogenic proteins escape the chaperon-assisted folding process and convert from their
native conformational state into diverse structures (Dobson 2001, Maltsev et al. 2011).
Misfolded proteins have an increased tendency to accumulate as thread-like, highly ordered
aggregates called amyloid fibrils. Diseases associated with amyloid deposits are termed
‘amyloidoses’ (Table 1.1). Amyloidoses are generally classified according to the location of
amyloid deposition. Hence, an amyloid occurring in one site or one type of tissue is associated
with localised amyloid deposition, e.g., β-amyloid (Aβ), α-synuclein or prion protein. When
an amyloid is distributed in multiple tissues or organs, usually outside the brain, like in case of
transthyretin or β2-microglobulin deposition, we speak of systemic amyloidosis (Westermark
et al. 2007). What all amyloidoses have in common is the intra- or extracellular deposition of
fibrillar material. Although polypeptide precursors of fibrils do not share sequence identity or
structural homology, the resulted fibrils display features typical of amyloid.
According to the Nomenclature Committee of the International Society of Amyloidosis,
amyloid fibrils are defined as ‘an insoluble protein fibril that is deposited, mainly, in the
extracellular spaces of organs and tissues as a result of a sequence of changes in protein
folding that results in a condition known as amyloidosis’ (Sipe et al. 2010). The features
of fibrils include distinctive appearance in electron microscopy (EM), typical cross-β X-ray
diffraction pattern, and binding of Congo red (CR) with a characteristic green birefringence
(Westermark et al. 2005). For distinction purposes, synthetic protein fibrils displaying some
1
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amyloid characteristics are being referred to as ‘amyloid-like’ fibrils (Sipe et al. 2010).
Table 1.1. Diseases associated with the amyloidogenic aggregation and deposition
Disease Precursor polypeptide chain Native structure
Alzheimer’s disease Aβ-protein precursor
(AβPP)
IUPC
Spongiform encephalopathies Prion protein IUPC (residues 1–120)
α-helical (residues 121–230)
Parkinson’s disease α-Synuclein IUPC
Frontotemporal dementia
with Parkinsonism
Tau IUPC
Huntington’s disease Huntingtin Mainly IUPC
British familial dementia ABriPP IUPC
Danish familial dementia ADanPP IUPC
Systemic AL amyloidosis Ig light chains or fragments All-β, Ig-like
Systemic AA amyloidosis Serum amyloid A protein All-α, unknown fold
Dialysis-related amyloidosis β2-microglobulin IUPC
Medullary carcinoma of the thyroid Calcitonin IUPC
Finnish hereditary amyloidosis Gelsolin IUPC
Type II diabetes Islet amyloid polypeptide IUPC
Insulin-related amyloidosis Insulin A Insulin B All-α, insulin-like
Aortic medial amyloidosis Lactadherin Unknown
Lysozyme amyloidosis Lysozyme α+β, lysozyme fold
Icelandic hereditary cerebral
amyloid angiopathy
Cystatin C α+β, cystatin-like
IUPC: intrinsically unfolded polypeptide chain. Sources: Fändrich (2007), Chiti and Dobson (2006),
Sunde and Blake (1998)
1.1.2 Onset and epidemiology of Alzheimer’s disease
Alzheimer’s disease (AD) has been first described by Alois Alzheimer in 1906. He
reported presence of extracellular clumps (‘senile plaques’) and intracellular tangled bundles
of fibres (‘neurofibrillary tangles’) in the post-mortem brain tissue of a woman who suffered
from very severe cognitive impairment (Alzheimer 1906).
AD is nowadays the most prevalent cause of dementia, and one of the major health
concerns of ageing societies (Jakob-Roetne and Jacobsen 2009). In 2005, the estimated
number of people with AD was 24.3 millions. It is predicted that 42.3 millions will have
developed AD symptoms by 2020, and 81.1 million will be afflicted by 2040 (Ferri et al.
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2006). Currently, 10% of the individuals over 65 years, and 40% of 85 years old are estimated
to be affected with AD (Morgan 2011).
Two forms of this neurodegenerative disease are usually referred to in the literature: very
rare, early-onset and late-onset AD (Myers and Goate 2001). The late onset is generally
sporadic and by far the dominating form of AD, while the early onset is rare (5% of the cases)
and mainly found to be familial. Mutation in presenilin 1 (PS1), presenilin 2 (PS2), and
β-amyloid precursor protein (AβPP) genes are typically associated with the early onset AD
(Suh and Checler 2002). PS1 and PS2 genes are part of the large proteolytic machinery, which
processes AβPP (Jakob-Roetne and Jacobsen 2009). Mutations in the AβPP gene, located on
chromosome 21, lead to the increased production of Aβ peptides, while PS1 (chromosome 14)
and PS2 (chromosome 1) point mutations can result in the enhanced proteolytic cleavage of
AβPP (Selkoe 2001). The late onset AD is mainly age-related and usually develops after the
age of 60, but the exact cause of the appearance of this form of dementia is a matter of debate.
Several genetic risk factors are potentially involved, among which apolipoprotein E4 gene
may play the most prominent role (Maltsev et al. 2011). Recently discovered clusterin and
complement receptor 1 are also thought to be AD risk factors (Eisenstein 2011). However,
also environmental factors, such as decreased physical, mental, and social activity or high
cholesterol diet, were suggested to be correlated with the development of this most common
form of dementia (DeWeerdt 2011).
1.1.3 Molecular background of AD
The β-amyloid plays a pivotal role in the pathogenesis of AD. This small 4 kDa peptide
is formed due to the proteolytic processing of the bigger transmembrane protein—AβPP. The
physiological role of AβPP is still to be elucidated, but putatively AβPP may act as a cell
surface receptor, and could be involved in synapse formation and neuronal iron transport
(Zheng and Koo 2011). AβPP undergoes several post-translational modifications, one of
which is a proteolytic cleavage with α-, β- and γ-secretases (Hardy and Selkoe 2002). α-
secretase cleavage does not play a pathological role in AD (as it cleaves AβPP within the
Aβ sequence), and is frequently suggested to be protective (Lichtenthaler and Haass 2004).
The action of β- and γ-secretases releases 37–42 amino acid Aβ peptide fragments. β-
secretase cleaves the extracellular, hydrophilic N-terminal part of AβPP, and γ-secretase
releases the hydrophobic, membrane-inserted C-terminal fragment (Figure 1.1). Aβ40 is the
most abundant form in the brain, but Aβ42 shows a stronger correlation with the neurological
symptoms of Alzheimer’s disease (Selkoe 2001).
Aβ peptide undergoes several chemical modifications. The N-terminal truncation at
3
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positions 3 or 11, as well as the modification with pyroglutamate appear most relevant
pathologically (Jakob-Roetne and Jacobsen 2009).
Figure 1.1. Processing of AβPP. Sequen-
tial cleavage of APP by β- and γ-secretases
leads to the production of Aβ40 or Aβ42 pep-
tides, and subsequent release into extracellular
space.
1.1.4 Amyloid hypothesis
Despite intensive research to date, AD is still not curable. Definite diagnosis requires post-
mortem analysis of the brain (Williams 2011); up to date physical and mental exercises are
considered as most effective preventive measures (DeWeerdt 2011), and only symptomatic
treatment is applied. The exact cause of the AD is still under debate. However, the
amyloid hypothesis formulated by Hardy and Allsop (1991) is compelling. This hypothesis
states that aggregating and accumulating cerebral Aβ peptide is the driving force of the AD
pathogenesis. Remaining disease processes, like tau hyperphosphorylation and neurofibrillary
tangle formation, could be secondary events, resulting from the imbalance between Aβ
formation and clearance (Figure 1.2; Hardy and Selkoe 2002). Recent study of Jakob-Roetne
and Jacobsen (2009) also showed that the Aβ40:Aβ42 ratio, shifted in favour of the latter,
positively correlates with the occurrence of dementia symptoms. Growing evidence indicates
that small soluble Aβ oligomers, but not the monomers or amyloid fibrils, are the main culprits
of the neurodegeneration in AD (Lambert et al. 1998). The extracellular deposition of the
insoluble amyloid plaques in the brain was suggested to constitute an inactive reservoir, not
contributing to the disease pathology (Hardy and Selkoe 2002).
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Figure 1.2. Amyloid cascade hypothesis.
Adapted from Haass and Selkoe (2007).
1.1.5 Role of Aβ aggregation in AD aetiology
It is well established that the aggregation of Aβ peptide is central to the pathology
of AD. The aggregation of Aβ is a nucleation-dependent process, with two well-resolved
phases. The first phase – the lag phase – is concentration-dependent, and involves Aβ nuclei
formation. The second phase – the exponential growth phase – includes rapid association
of Aβ molecules with the nucleus (Chiti and Dobson 2006). The extracellular deposition of
amyloid fibrils as plaques represents the final stadium of the Aβ aggregation. Among few Aβ
isoforms, the Aβ40 and Aβ42 fibrils are pathologically the most relevant. Even though Aβ42
fibrils better correlate with the symptoms of AD, Aβ40 fibrils constitute a major component
of the amyloid plaques. Dense core amyloid plaques are a hallmark of AD, but the pathway
of Aβ assembly also includes several on- or off- pathway intermediates. A simplified Aβ
peptide aggregation pathway is presented in Figure 1.3. The Aβ intermediates include many
structurally diverse species, described under different names (Bitan et al. 2005). The general
terms ‘oligomers’ and ‘protofibrils’ have been coined to categorise the two most distinct
groups. Spherically shaped oligomers precede appearance of protofibrils, which are the next
5
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stage in Aβ assembly cascade – the intermediate step between oligomers and fibrils. The
protofibrils are curvilinear aggregates – structurally similar to oligomers, but morphologically
resemble fibrils (Scheidt et al. 2011).
Figure 1.3. Aggregation of Aβ peptide. Schematic illustration of the Aβ peptide assembly shows
two intermediate states, i.e., oligomers and protofibrils, as well as the final aggregation state – mature
fibrils.
1.2 Structure and properties of amyloid fibrils
1.2.1 Morphological appearance
Aβ40 fibrils have a typical appearance on transmission electron microscopy (TEM)
images. They represent long, linear structures with diameter of 10–25 nm, and a length of
1 µm (Fändrich et al. 2011). Another typical feature of mature Aβ fibrils are cross-over
distances, which represent apparent constrictions of the fibril width, as observed with TEM
projections (Figure 1.4; Meinhardt et al. 2009). Aβ40 fibrils are similar to the other amyloid
fibrils: the width, cross-over distances or cross-sectional structures vary between single fibrils
prepared under identical conditions, or even derived from the same sample (Meinhardt et al.
2009). As suggested by Pedersen and Otzen (2008), the distinct appearance of fibrils might
result from the absence of structure controlling mechanisms in case of non-functional protein
conformations.
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Figure 1.4. Negatively stained and cryo-EM im-
ages of Aβ40 fibrils. Cross-over distances and
fibril width measurements are demonstrated on the
same fibril (left panel). 3D reconstruction of the
Aβ40 fibril obtained from the cryo-EM image (right
panels). Images after Meinhardt et al. (2009) and
Sachse et al. (2008), modified.
1.2.2 Structural characteristics
For the last two decades, the structure of amyloid fibrils has been a matter of intense
investigation. Aβ fibrils are composed of insoluble, and thus non-crystalline material.
Naturally occurring fibrillar polymorphismmakes their examination more difficult (Meinhardt
et al. 2009). However, due to recent development of high resolution techniques, like solid state
nuclear magnetic resonance (ssNMR), or cryo-EM, several structural models of Aβ fibrils at
near-atomic resolution have been proposed (Lührs et al. 2005, Petkova et al. 2006, Sachse et al.
2006, Sawaya et al. 2007, Sachse et al. 2008). Initially, the structure of the fibrils was based
on X-ray diffraction measurements (Sunde et al. 1997). The cross-β conformation, reflected
in regular main chain spacing of 4.7 Å (Marshall and Serpell 2009), and variable distances
in fibril cross-section of 5–12 Å (Fändrich 2007), is a well-established structural motif of
amyloid fibrils. The cross-β conformation consists of β-strands running perpendicular to the
main fibril axis. Recent cryo-EM study revealed an improved fibril structure at 8 Å resolution
(Figure 1.5a; Sachse et al. 2008). 3D reconstruction of Aβ40 fibrils showed that mature
fibrils consist of two partially overlapping protofilaments (Figure 1.5b; Sachse et al. 2008).
According to this reconstruction, each protofilament encompasses juxtaposed paired β-sheet
structures. These findings are in good agreement with the steric zipper structure, demonstrated
earlier by Sawaya et al. (2007).
In comparison, cryo-EM structure of Aβ42 fibrils revealed a slightly different arrangement
(Figure 1.5c). Mature Aβ42 fibril comprises only one protofilament, and the β-sheet packing
is tighter (Schmidt et al. 2009). Schmidt et al. (2009) also showed that protofilament structures
of Aβ40 and Aβ42 fibrils are very similar, and that each cross-β repeat contains an equal
number of Aβ molecules.
7
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(a) (b) (c)
Figure 1.5. Comparison of Aβ40 and Aβ42 fibrils structure. Three distinct fibril morphologies
are based on reconstructions of Aβ40 and Aβ42 fibrils (a). Aβ40 fibril consists of two protofil-
aments (structure) with the similar organisation of Aβ molecules (model) as in Aβ42 fibril (b).
Cross-section of Aβ42 fibril shows presence of one protofilament (structure) and possible peptide
position (model) (c). Images after Schmidt et al. (2009).
1.2.3 Tinctorial characteristics
An elongated and regular structural pattern implies an additional distinct fibril character-
istic, namely high affinity for amyloid-dyes: CR and Thioflavin T (ThT) (Figures 1.6a and
1.6b). This affinity allows easy detection of amyloid fibrils. This methods, however, are not
free from limitations – such as sensitivity to the solution and staining conditions (Westermark
et al. 2005, Fändrich 2007). The mechanism of binding of mature fibrils with these dyes
is not fully elucidated, but in the case of ThT binding, it may be based on the interaction
with aromatic and aliphatic side chains of amyloid fibrils (Biancalana and Koide 2010). CR
binding probably relies on the interaction with charged and hydrophobic residues on amyloid
fibrils (Frid et al. 2007). However, a previous study on insulin fibrils suggests that aromatic
residues could also be involved in amyloid deposits-CR binding (Turnell and Finch 1992).
Aβ oligomers show decreased affinity for amyloid ligands like ThT or CR (compared to
fibrils), but they strongly interact with 1-anilino-8-naphthalene sulfonate (ANS; Figure 1.6c),
a fluorescent dye (Haupt et al. 2012). ANS binds to hydrophobic surfaces of proteins
(Matulis et al. 1999). In contrast, Aβ fibrils do not show a significant interaction with ANS
(Figure 1.6d).
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(a) Congo red
(b) Thioflavin T (c) 1-anilino-8-
naphthalene
sulfonate
(d) Absorption and fluorescence
Figure 1.6. Structure of amyloid-binding dyes and their interaction with amyloid
conformers. Strong ThT fluorescence signal was obtained with Aβ fibrils (a); CR
absorption difference was high for fibrils but low for oligomers (b) ; high fluorescence
signal indicates strong interaction of oligomers with ANS (c). Images after Haupt et al.
(2012) and Fändrich (2012), modified.
1.2.4 Amyloid fibrils in AD: inert or protective deposits – or a potent toxin?
A strong correlation between the level of soluble Aβ and the deterioration of neuronal
functions has been reported in many studies (McLean et al. 1999, Dahlgren et al. 2002, Lue
et al. 1999, Selkoe 2008, Shankar and Walsh 2009, O’Nuallain et al. 2010). Even though
soluble oligomers are the putative cause of AD (Kirkitadze et al. 2002), cytotoxic effects of
Aβ fibrils were also observed. Initially, their toxic impact on cultured primary hippocampal
neurones was shown by Lorenzo and Yankner (1994) and, more recently, by Petkova et al.
(2005). Results obtained from two different populations of Aβ fibrils indicate that at least
some fibril morphologies may be pathologically relevant (Figure 1.7; Petkova et al. 2005,
Schmitz et al. 2004). Geula et al. (1998) found that Aβ fibrils cause the activation of microglia
9
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and neuronal loss in primate brains. In contrast, some indication exists that accumulation
of Aβ peptide in form of insoluble deposits performs a protective function. Holmes et al.
(2008) showed that targeting of the Aβ deposits by vaccination did not prevent progressive
neurodegeneration, but instead led to undesirable side effects i.e., meningoencephalitis and
leukoencephalopathy (Orgogozo et al. 2003).
Figure 1.7. Toxicity of Aβ40 fibrils on
cultured primary embryonic rat hip-
pocampal neurones. Two different popula-
tions of fibrils were examined: one growing
in the quiescent and second subjected to
agitation. Viability of the cultured neurones
was measured after 24 h or 48 h exposure
to Aβ40 fibrils. Image after Petkova et al.
(2005).
Whether harmless or toxic, the effect of fibrils in the demented brain needs to be
elucidated. It is well known that they constitute the most abundant amyloid aggregates in
the brain of people with AD; hence, Aβ fibrils are the matters of comprehensive structural
and functional investigations.
1.2.5 Common structure of amyloid fibrils derived from various polypeptides
It has been demonstrated that amyloid fibrils derived from different polypeptide precursors
display similar structural characteristics (Chiti and Dobson 2006, Fändrich et al. 2009). Fibrils
formed from insulin, glucagon, yeast prion protein Ure2p or β2-microglobulin provide good
examples. These fibrils have been grown from different polypeptides and differ morpholog-
ically (short or long, straight or curvilinear). Nonetheless, all of them posses the β-sheet
amyloid-like structure (Haupt et al. 2011a) and bind ThT and CR dyes, along with a shared
ability to produce the characteristic reflection pattern in X-ray diffraction. Remarkably, not all
amyloid aggregates are associated with a disease, for instance glucagon (Pedersen and Otzen
2008) and apomyoglobin fibrils (Fändrich et al. 2006) are pathologically irrelevant.
10
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1.3 Characterisation of Aβ oligomers
1.3.1 Diversity of oligomeric Aβ aggregates
Accumulating evidence suggests that the Aβ oligomeric aggregates are primary toxic
species that causes AD. A number of on- or off-pathway Aβ intermediates have been
described in the literature. However, acquisition of homogeneous batches of Aβ peptides,
and establishing of a reproducible protocol for oligomer preparation pose major challenges.
Metastable character of oligomeric aggregates, and their vulnerability to solution conditions
make them prone to aggregation. Hence, in order to examine the properties of oligomeric
aggregates, it is necessary to subject them to a temporary arrest. This may be achieved with
various methods, e.g., by lyophilisation, or by ligand binding.
Oligomeric species described in the literature differ in size, shape, aggregation pathways,
and mechanism of toxicity (Bitan et al. 2005). In addition, the vague nomenclature of the
oligomeric species is confusing: a given entity is described under different names (Bitan
et al. 2005). Commonly described intermediate Aβ species include protofibrils, annular
protofibrils, and oligomers (see Table 1.2 for a summary). Protofibrils are structurally similar
to mature Aβ fibrils, but they can be distinguished by their curvilinear shape and weaker
binding affinity to amyloid ligands, i.e., ThT and CR (Walsh et al. 1999, Goldsbury et al.
2000). Annular protofibrils are characterised by a pore-like shape. Disruption of the cell-
membrane, the putative toxicity mechanism of this species, is attributable to this property
(Lashuel et al. 2002). While morphological properties of protofibrils and annular protofibrils
allow their differentiation, the group called ‘oligomers’ includes species displaying a whole
repertoire of shapes and structures. This diverse group contains species such as Aβ*56
oligomers, amyloid-derived diffusible ligands (ADDL), and globulomers, to name but a few.
Aβ oligomers are generally defined as partially soluble, metastable conformers derived
from Aβ peptides, varying in diameter from 2 to 50 nm. Oligomers include species ranging
in size two (dimers) and several hundreds of monomers per unit. Species of up to 50 kDa are
often referred to as low molecular weight (LMW) oligomers (Bitan et al. 2003); those above
50 kDa are referred to as non-fibrillar, high molecular weight (HMW) oligomers.
Most oligomeric species described in the literature were prepared from synthetic Aβ
peptides, according to established protocols. The remaining ones originated from naturally
occurring Aβ species, detected and isolated post-mortem from AD brains (Haass and Selkoe
2007). For example, 70 kDa or larger aggregates, containing Aβ dimers, have been isolated
from human brain tissues (Shankar et al. 2008). Aβ*56 oligomers were purified from brains of
AD transgenic mice (Lesne et al. 2006). Oligomeric species prepared in vitro from synthetic
11
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Table 1.2. Oligomeric Aβ species
Oligomeric species Aβ isoform Characteristics
Protofibrils Aβ40, Aβ42 Curvilinear, soluble assemblies; diameter: 6–8 nm and length
up to 200 nm (derived from AFM and TEM); MW: >100 kDa
(according to SEC) (Harper et al. 1997, Walsh et al. 1997,
Broersen et al. 2010); bind to CR and ThT (Habicht et al.
2007); high level β-sheet content (as stated with CD and X-ray
diffraction) (Walsh et al. 1999, Habicht et al. 2007)
Annular protofibrils
(APF)
Aβ42 Ring-like shape with central opening; diameter: 8–25 nm;
substantial β-sheet structure ( as stated with CD) (Kayed et al.
2009); 36-mers (out of 6 hexamers) (Lasagna-Reeves et al.
2011)
Aβ-derived diffusible
ligands (ADDL)
Aβ42 Soluble, globular structure; diameter: 4.8–5.7 nm;
MW: 17–42 kDa (derived from AFM); disrupt LTP in rats
(Lambert et al. 1998, Chromy et al. 2003, Lacor et al. 2004)
Aβ*56 Aβ42 Dodecamer isolated from the brains of AβPP transgenic mice;
MW: 56 kDa (Lesne et al. 2006)
Globulomers Aβ42 Diameter: 1–5 nm; MW: 16–64 kDa (Barghorn et al. 2005);
rich in β-sheet structure (as stated with ATR-FTIR)(Eckert
et al. 2008)
Low n-oligomers Aβ40, Aβ42 SDS resistant dimers and trimers; diameter: 2–7 nm;
MW: 8–12 kDa; significant β-sheet content (as stated with CD)
(Walsh et al. 2002, Bitan et al. 2003, Ono et al. 2009)
Modified after Haass and Selkoe (2007) and Meinhardt (2010); MW: molecular weight
or recombinant Aβ peptide include ADDL, globulomers or annular protofibrils (Lambert et al.
1998, Gellermann et al. 2008, Caughey and Lansbury 2003).
Because some entities have been described by different investigators, it is necessary to
verify their identity. For some oligomeric intermediates, it also needs to be established
whether or not they share a common aggregation pathway. Finally, toxic and non-toxic Aβ
species need to be identified and categorised. Small ligands, such as Aβ-specific antibodies,
may prove particularly helpful in fulfilling these tasks.
1.3.2 Structure of Aβ oligomers
The structural study of Aβ oligomers has been hindered by difficulties in obtaining
homogeneous populations that are free from monomers or fibrils. Furthermore, the inability
to acquire atomic-level structural information about different types of Aβ oligomers is due to
their small size, metastable nature, and structural sensitivity to the conditions of preparation.
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Access to oligomer structure would allow better understanding of Aβ toxicity, mediated by
assembly process. The most common methods used for determination of oligomers’ size and
weight are the polyacrylamide gel electrophoresis (PAGE) with presence of sodium dodecyl
sulphate (SDS), or native PAGE, as well as size exclusion chromatography (SEC) (Bitan et al.
2003, 2005, Sandberg et al. 2010). However, these techniques are not free from limitations.
For instance, SDS can promotes aggregation of the amphipathic molecules and thus SDS-
PAGE may produce false results in terms of size of the Aβ oligomers (Bitan et al. 2005). The
main drawback of the SEC is a relatively low resolution, compared to SDS-PAGE (Bitan et al.
2005). Morphological assessment of various oligomeric forms is usually performed with TEM
or atomic force microscopy (AFM) (Bitan et al. 2005, Glabe 2008, Mastrangelo et al. 2006).
Current structural studies of Aβ intermediates are based on spectroscopic methods, of which
ssNMR provides the best resolution (Ahmed et al. 2010). Presence of the antiparallel β-sheet
structure in Aβ oligomeric species was suggested by several attenuated total reflectance (ATR)
Fourier transform infrared spectroscopy (FTIR) studies (Habicht et al. 2007, Eckert et al.
2008, Cerf et al. 2009). Aβ42 oligomers investigated by Ahmed et al. (2010) with ssNMR
also showed significant content ofβ-sheet structure, but organised in different, antiparallel and
less ordered manner than in Aβ40 oligomers or Aβ42 fibrils. Indication of antiparallel β-sheet
structure in certain oligomer types are intermolecular hydrogen bonds (Sandberg et al. 2010).
However, ssNMR study conducted by Chimon et al. (2007) revealed that Aβ40 spherical
oligomers possess amyloid-like parallel β-sheet structure.
1.3.3 Impact of Aβ oligomers on the aetiology of AD
The original Aβ hypothesis, formulated by Hardy and Higgins (1992); was based on
the assumption that AD is caused by extracellular deposition of fibrils in amyloid plaques.
However, several more recent reports have indicated that neurodegeneration begins before
fibrillar aggregates appear, and that it might be independent of the number of deposited
plaques (Hsia et al. 1999, McLean et al. 1999). This discovery has shifted the attention of the
scientists to soluble species, and revealed the need for the invention of therapeutic solutions
directed against prefibrillar species. Currently, soluble oligomers are seen as the most
important mediators of amyloid toxicity (Jakob-Roetne and Jacobsen 2009). Compared with
fibrils, the correlation of oligomers with occurrence of AD symptoms is stronger (McLean
et al. 1999, Dahlgren et al. 2002, Lue et al. 1999, Selkoe 2008, Shankar and Walsh 2009,
O’Nuallain et al. 2010). Such effects of oligomers as inhibition of long-term potentiation
(LTP; Walsh et al. 2002), neuronal loss, or synaptic plasticity deterioration has been shown
in AD mouse models (Lesne et al. 2006).
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Many oligomeric structures (e.g. ADDL) have been reported to be toxic in neuronal cell
cultures (Lambert et al. 1998). Aβ42 globulomers have been detected in amyloid deposits in
AβPP Tg2576 transgenic mice, as well as acquired in vitro by incubation under established
conditions (Barghorn et al. 2005). Neurotoxic, soluble Aβ dimers and trimers have been
shown to inhibit LTP in rats (Walsh et al. 2002) and Aβ*56 oligomers were also reported
to impair memory (Lesne et al. 2006). However, the correlation between neurotoxicity and
structure of oligomeric conformers derived from the AD brain tissues, and those formed by the
incubation of the synthetic Aβ peptide, remains unclear. Nonetheless, the neurotoxic impact
of both synthetic a and wild-type oligomers on neurones is well-documented (McLean et al.
1999, Hsia et al. 1999). The neuronal membrane permeabilisation has been put forth as a
putative mechanism of destruction of neurones by annular protofibrils (Lasagna-Reeves et al.
2011). Impairment of mitochondria by Aβ42 oligomers was observed in tau transgenic mice
(Eckert et al. 2008). However, the exact mechanism of how oligomers exert the toxic effect is
poorly known.
1.4 Toxicity mechanism and therapeutic approaches in AD
Despite the controversy about the impact of Aβ fibrils and oligomers on the neuronal
toxicity and some contradicting data on this topic, the key role of Aβ aggregation in AD
pathology is well documented. Therefore, all Aβ aggregates are targeted therapeutically.
While Aβ toxicity might be mediated in several ways, the exact mechanism remains unknown.
Aβ aggregates may interact with cellular components like membranes, mitochondria or other
macromolecules (Eckert et al. 2008). In consequence, this may lead to oxidative stress,
disruption of important cellular functions like efflux of calcium ions, impairment of axonal
transport or synaptic communication (reviewed by Chiti and Dobson 2006). Currently, neither
definitive diagnostic markers, nor effective therapeutic tools for AD are available. In this
context, anti-Aβ antibodies are gaining attention. They may reveal some pharmacological
potential, or may prove useful for structural Aβ studies.
1.4.1 Immunotherapeutic strategies to combat Aβ toxicity
Prevailing evidence indicates that, among several therapeutic strategies against toxicity
of Aβ, immunotherapeutic approaches are the most promising. Both active and passive
immunotherapy have been demonstrated to be effective in reducing amyloid burden in animal
models (Lombardo et al. 2003, Schenk et al. 2005). Active immunotherapy uses antigen
stimulation of the host immune system to produce antibodies against applied antigens. It
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has been proven useful in improving the cognitive decline by reducing the amyloid plaque
load in transgenic mouse models (Morgan et al. 2000, Lemere et al. 2000, Weiner et al.
2000, McLaurin et al. 2002) and elevating the Aβ level in the periphery (Lemere et al. 2003).
However, the first clinical trials with the active vaccine AN1792 (ELAN / Wyeth) have been
halted, because 6% of patients developed meningoencephalitis (Schenk 2002). Currently,
several Aβ vaccines are undergoing clinical trials (Lemere and Masliah 2010, Delrieu et al.
2011). These include second-generation vaccines like ACC-001, CAD-105 or V950, which
were designed to avoid stimulation of the adverse immune responses (Lemere and Masliah
2010, Delrieu et al. 2011).
In passive immunotherapy, antibodies or antibody fragments specific against certain Aβ
epitopes are provided externally. This eliminates the need of host immune response develop-
ment, which is often problematic in elderly patients. Beneficial effects of passive vaccination,
including disintegration of pre-existing Aβ deposits (Bard et al. 2000) and improvement of
cognitive functions (Wilcock et al. 2004), have been demonstrated in AD transgenic mice.
Due to the complexity of the topic, and the relevance for this dissertation, I will further focus
only on the passive vaccination solutions.
1.4.2 Putative mechanisms underlying the Aβ clearance by antibodies
Although the question how passive vaccination might rescue cognitive functions in AD
brain remains unanswered, some mechanisms describing antibody-mediated Aβ clearance
have been proposed (Figure 1.8). The peripheral sink mechanism hypothesis is based on the
observation made by DeMattos et al. (2001). Peripheral injection of the 266 monoclonal
antibody, which binds with picomolar affinity to soluble Aβ, reduced the amyloid load in the
brains of transgenic mice. Thus, peripheral injection of the anti-Aβ antibodies may cause
efflux of the parenchymal Aβ, by shifting the Aβ ratio between blood plasma and the central
nervous system (CNS).
Fc receptor-mediated phagocytosis by activated microglia is the second proposed mech-
anism (Istrin et al. 2006). It has been demonstrated that a small amount of peripherally
administrated antibodies reaches the brain parenchyma of PDAβPP transgenic mice and
triggers the microglia-dependent phagocytosis of amyloid deposits (Bard et al. 2000).
Proponents of the third mechanism, the direct resolution hypothesis, suggested that the
antibodies against the N-terminal part of Aβ are able to directly resolve the Aβ fibrils and
remove the Aβ deposits (Frenkel et al. 2001, Solomon et al. 1997, McLaurin et al. 2002).
Hence, this mechanism could also constitute the base for the therapeutic effect.
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Figure 1.8. Schematic illustrations presenting putative mechanisms of Aβ clearance by antibod-
ies. Microglia mediated Aβ clearance (a), direct resolution mechanism (b), peripheral sink hypothesis
(c). Images after Citron (2004). BBB: blood–brain barrier.
1.4.3 Existing antibodies against Aβ
A whole set of polyclonal sera and monoclonal antibodies have emerged against different
Aβ conformers. Anti-Aβ antibodies can be roughly grouped into two categories – sequence-
specific and conformation-specific binders. The first group includes the antibodies which
bind to the polypeptide sequence of Aβ; their specificity is broader. For instance, 3D6 and
82E1 monoclonal antibodies bind the N-terminal part of Aβ, and were also effective in the
reduction of the amyloid deposits in human brain (Shankar et al. 2008). Aβ C-terminal (2G3,
21F12) and mid-region (266) specific antibodies were unsuccessful in Aβ precipitation and
preventing neuronal deterioration (Shankar et al. 2008).
The second group of antibodies recognises a certain structural motif on proteins, which is
independent of the amino acid sequence. Kayed and coworkers isolated polyclonal sera (A11,
OC and α-APF) specific to several soluble Aβ conformers (Kayed et al. 2003, 2007, 2009).
These polyclonal antibodies are specific to three different types of Aβ oligomers: prefibrillar
oligomers, fibrillar oligomers and annular protofibrils (Kayed et al. 2010). The other example
of conformation-specific binders constitute WO1 and WO2 monoclonal antibodies generated
by immunisation, which bind to Aβ fibrils (O’Nuallain and Wetzel 2002).
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1.4.4 Conventional antibodies versus recombinant antibodies
The previous examples constitute but a few out of many Aβ binders reported in the
literature. However, their mechanism of binding is poorly understood. Most of the currently
available Aβ binders have been obtained by means of animal immunisation, which is often
an expensive and time-consuming approach. Additionally, the generation of monoclonal
antibodies by immunisation requires special cell culture systems and involves exploitation
of animals (Donzeau and Knappik 2007).
Recombinant antibodies constitute a different class of amyloid binders. They are gener-
ated from synthetic antibody gene libraries. Their production eliminates many disadvantages
associated with generation of antibodies by immunisation. First of all, the generation of anti-
bodies in vitro circumvents the problem of animal use. Second, all reagents are monoclonal,
making them suitable for high-throughput screening (Krebs et al. 2001). Moreover, recom-
binant antibodies are easy to express in large quantities with the use of the same expression
system (Habicht 2002). Finally, the accessibility of DNA sequences of recombinant antibodies
facilitates genetic manipulations, thus giving way to the generation of novel downstream
reagents with modified properties (Plückthun and Pack 1997, Plückthun 1992).
This thesis will cover selection of conformation-specific binders directed against β-
amyloid from a synthetic phage library and their mode of action.
1.5 Selection of antibody fragments from a recombinant DNA library
1.5.1 Display technologies
Naive and recombinant libraries were constructed to enable in vitro or in vivo selec-
tion of antibodies (Sergeeva et al. 2006). Several different display approaches have been
successfully implemented to generate recombinant antibodies directed against a variety of
antigens (Sergeeva et al. 2006). These include bacterial, yeast and mammalian cell surface
display, as well as ribosome and phage display. Besides the possibility of generation of highly
specific binders, display technologies facilitate the improvement of antibody properties, like
affinity or stability. The main advantages of the displaying methods include: the possibility
of application against a vast range of antigens, and the ability of adjusting the selection’s
conditions to particular needs (Ponsel et al. 2011). Among aforementioned techniques,
ribosome and phage display earned most attention.
Phage display has been established by Smith in 1985 (Smith 1985). Nowadays, it is the
most commonly applied display method used for read out of combinatorial antibody libraries
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(Ponsel et al. 2011). Phage display involves cloning the DNA coding for a peptide or a protein
to the M13 bacteriophage genome. Fusion of a gene fragment coding for an antibody to the
coat protein of M13 phage facilitates the expression of the antibody on the surface of the
phage as the coat-fusion protein; hence, provides a physical link between the genotype and
phenotype of the protein. As a result, recombinant proteins are displayed on the surface of
the M13 bacteriophage – usually as a fusion with phage coat protein III. M13 is a single
strand filamentous bacteriophage, which consists of 10 genes (Figure 1.9; Arap 2005). The
major capsid protein, pVIII, exists in approximately 2700 copies (Arap 2005). The minor
capsid pIII protein, used for the protein fusion, is present in 5 copies (Sergeeva et al. 2006).
Assembly of the phages and expression of the antibodies takes place in the periplasmic
space of Escherichia coli (E. coli). The phage display system, used to generate antibodies
directed against β-amyloid – which are the matter of this thesis – consists of two components:
phagemid vector and helper phage. The monovalent expression of the antibodies on the phage
surface and their small size are the major advantages of the phagemid use. It enables the
construction of larger libraries. However, the overall size of libraries displayed on phages
is limited by the efficiency of E. coli transformation (Vaughan et al. 1996). Phage display
selection of antibodies proves to be a very fast and effective method of antibody generation,
in comparison to animal immunisation (Habicht et al. 2007, Lafaye et al. 2009). Competitive
selection conditions limit unsolicited cross-reactivity and the selection just sequence–specific
binders.
   II                             X           V      VII  IX  VIII                             III                              VI                           I  
         
       
      
      
      
     
     
  IV
     
     
     
     
     
     _
       
       
       +
M13
6.4 Kb
tran
scriptio
n
promoters
terminators
ori
(a)
pIX
pVII
pVIII
pVI
pIII
(b)
Figure 1.9. Schematic representa-
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after http://viralzone.expasy.org and
Arap (2005), modified.
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1.5.2 Synthetic antibody library based on the Camelidae immunoglobulin (Ig)
The subject of my dissertation are Camelidae variable heavy chain domain (VHH)
antibodies and their interaction with Aβ conformers. The phage display library generated
at the Hans Knöll Institute (HKI; Jena, Germany) was used for the selection of the antibody
fragments directed against β-amyloid conformers. The fully synthetic, combinatorial HKI
phage library consists of VHHs of camelid heavy chain antibodies (HCAb) (Habicht 2002).
Camelidae contain two distinct classes of the antibodies, conventional and HCAb. HCAb
significantly differ from conventional antibodies, because they are devoid of the light chain
(Figure 1.10); thus, the whole specificity of the camelid antibody is encoded within the heavy
chain (Hamers-Casterman et al. 1993). VHHs of the HCAb, referred also as ‘nanobodies’,
are the smallest possible antigen-binding fragments, which can be generated in nature (Huang
et al. 2010). The small size of this antibody fragment is its great advantage. It penetrates
tissues better, thus providing easier access to the antigens. Furthermore, the increased stability
of the VHH domain is caused by the replacement of the hydrophobic regions in framework 2,
and by the presence of the intramolecular disulphide bond (Ewert et al. 2002, Van der Linden
et al. 1999). In addition, the intramolecular disulphide bond makes it functionally suited for
the expression in periplasm of E. coli. VHH antibodies are gaining increasing attention among
amyloid researchers. They have proved to be effective in the elucidation of the mechanism of
Aβ aggregation and were demonstrated to ameliorate amyloid-mediated cytotoxicity (Habicht
et al. 2007, Lafaye et al. 2009, Kasturirangan et al. 2010b,a, Streltsov et al. 2011).
Light chain
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VHH
VHH
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CH2
CH3
Fc Fv
ScFv
Fa
b
Antigen binding
fragments
CH2
CH3
Fc
VH
VL
Conventional antibody:
!"#$%&'"$ HCAb:
Figure 1.10. Comparison of the conventional
and CamelidaeHCAb. Fc: crystallisable fragment;
Fab: antigen binding fragment; CH: constant re-
gion; VH: heavy chain variable region; VL: light
chain variable region; ScFv: single chain variable
fragment. Image after Muyldermans (2001), modi-
fied.
Construction of the HKI VHH antibody library was based on the alignment of the 59
llama VHH sequences, and involved a three-step polymerase chain reaction (PCR) assembly
of randomised oligonucleotides coding for the framework and complementary determining
fragments. The big diversity of the HKI camelid library is due to the full randomisation of the
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complementarity determining region (CDR) positions, the length variations of the CDR3, as
well as some naturally occurring framework polymorphism (Habicht 2002).
1.6 Relevance of the B10 antibody fragment for the structural study of amyloid fibrils
1.6.1 Selection of the B10 antibody fragment
Habicht et al. (2007) developed an approach to select a binder to Aβ40 fibrils. This
approach is based on the recombinant library of VHH domains. The selection of the VHH
antibody against Aβ40 fibrils has been performed in a competitive environment. Aβ40 fibrils
served as bait for the phage display; a surplus of disaggregated, primarily monomeric, Aβ40
peptide was applied to prevent selection of sequence-specific binders. This phage display
selection generated an antibody fragment termed B10 (Habicht et al. 2007). B10 binds in
a conformation-specific manner to Aβ40 fibrils, but it reacts neither with disaggregated Aβ
peptides, nor with Aβ oligomers. The apparent dissociation constant (aKD) of B10 binding to
the fibrils, measured with surface plasmon resonance (SPR), was 475± 54 nM. Genetic fusion
of the B10 VHH domain to alkaline phosphatase (AP) yielded a dimeric protein formation
(termed B10AP). B10AP has an increased binding affinity to fibrils (KD = 7.22 ± 0.97 nM;
Habicht et al. 2007). The fusion of B10 with AP enables its detection in immunoassays,
and eliminates a need for a secondary antibody. The presence of the AP moiety facilitated
immunohistological staining of post-mortem AD brain slices; eleven of twelve confirmed
Alzheimer’s cases showed positive staining with B10AP, thus providing evidence for the
binding of B10AP to in vivo amyloid tissue deposits (Habicht et al. 2007).
1.6.2 Stabilisation of Aβ40 protofibrils by B10AP
B10AP recognises prefibrillar aggregates: a kinetic study of Aβ40 monitored with ThT
fluorescence and B10AP immunoblot staining revealed that the formation of the B10-epitope
precedes the appearance of ThT-positive fibrils (Habicht et al. 2007). Furthermore, B10AP
not only binds to prefibrillar aggregates, but also inhibits further aggregation. The monitoring
of the Aβ40 aggregation with ThT has shown that mature Aβ40 fibrils are formed only
in absence of B10AP, while presence of B10AP inhibits their formation. Finally, it was
confirmed with TEM imaging that B10AP prevents fibril formation by stabilising protofibrils
(Figure 1.11).
The ability to interact with protofibrils has been described for the WO1 anti-fibril antibody
(Williams et al. 2005), suggesting that protofibrils and fibrils share a common structure. A
recent ssNMR protofibril study also indicated this similarity (Scheidt et al. 2011). Even
20
INTRODUCTION
Figure 1.11. Aβ40 aggregation in presence or absence of B10AP. Formation of the ThT–positive
Aβ40 structures was potently inhibited by B10AP. Fibril formation was monitored with ThT fluores-
cence (left) and TEM (right). No ThT–positive Aβ40 fibrils were formed upon Aβ incubation with
B10AP presence. Analysis of the TEM images revealed that B10AP stabilises the protofibril stage.
Image after Habicht et al. (2007), modified.
though the structures of protofibrils and oligomers are similar, protofibrils encompass a
considerable part of β-sheet which recruits similar residues as fibrils (Scheidt et al. 2011,
Kheterpal et al. 2006). Hence, there may exist a similarity in how B10 recognises Aβ fibrils
and protofibrils.
1.6.3 Crystal structure of B10 implies the mechanism of recognition
The crystal structure of B10 (Figure 1.12a; Haupt et al. 2011b) has been resolved with
X-ray crystallography at 1.8 Å resolution by Isabel Morgado and her coworkers at the Max
Planck Research Unit (MPRU) in Halle. The antigen-binding surface of the conformation-
specific B10 antibody fragment was found to be completely flat, and thus structurally com-
patible with the even surface of the Aβ40 fibril. In comparison, sequence-specific antibodies
recognising the Aβ peptide usually contain a deep antigen-binding pocket which encompasses
the extended polypeptide chain (Basi et al. 2010).
The analysis of the B10 amino acid sequence has revealed that the CDRs are rich in
positively charged amino acids, while negatively charged amino acids are absent; the analysis
of the electrostatic surface confirmed that the binding site of B10 is strongly cationic, with
basic residues distributed throughout (Figure 1.12b; Haupt et al. 2011b). The peculiar
characteristics of B10 suggest that electrostatic interactions are involved in Aβ40 recognition,
but the actual mechanism requires to be elucidated.
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(a) (b)
Figure 1.12. B10 crys-
tal structure and electrostatic
surface. Ribbon diagram of
the B10 crystal structure; green:
CDR1; red: CDR2; blue:
CDR3 (a). Presentation of the
B10 electrostatic surface; blue:
basic region; red: acidic region
(b). Images after Haupt et al.
(2011b), modified.
1.6.4 Specificity of B10 binding to other amyloid fibrils
B10 has initially been demonstrated to bind to several amyloid fibrils, e.g., serum amyloid
A fibrils, or AL amyloid fibrils (derived from the Ig light chain; Habicht et al. 2007).
These fibrils do not share a similar sequence with Aβ40 fibrils. Nonetheless, they display
some typical amyloid characteristics. A further study of B10 specificity has shown that it
recognises neither globular β-sheet proteins, nor intrinsically disordered polypeptides (Haupt
et al. 2011b). These data are in agreement with the finding that B10 does not significantly
react with β-sheet-rich oligomers (Habicht et al. 2007). A better understanding of the B10
interaction with amyloid fibrils is necessary. It may facilitate the application of B10 as a
diagnostic tool in amyloid diseases. The detailed mechanism of B10 recognition will be the
matter of my thesis.
1.7 Selection of antibody fragments directed against Aβ40 oligomers
Further antibody fragments directed against Aβ conformers were isolated from the HKI
VHH library by Karin Wieligmann (HKI, Jena). Here, Aβ40 oligomers were used as an
immobilised target; freshly dissolved Aβ40 peptide in surplus served as a competitor in
the solution phase. Four rounds of selection were performed to generate three antibodies
(termed KW1, KW2, and KW3). The initial characterisation of the selected VHH domains
has shown a strong and selective interaction between KW1 and Aβ40 oligomers (Morgado
et al. 2012). The crystal structure of KW1, determined at 1.9 Å resolution, revealed a β-
sandwich fold structure with a hydrophobic binding region (Figure 1.13), encompassing an
aromatic benzamidine molecule from the crystallisation buffer (Morgado et al. 2012). None
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(a) (b)
Figure 1.13. Crystal structure and elec-
trostatic surface of KW1. Ribbon dia-
gram of the KW1 crystal structure; green:
CDR1; red: CDR2; blue: CDR3 (a).
Electrostatic surface potential of the KW1
crystal structure. Blue: basic region, red:
acidic region (b). Images after Morgado
et al. (2012), modified.
of the selected binders interacted considerably with more than one type of Aβ40 conformers;
all three antibody domains are thus conformationally specific: KW1 is specific to Aβ40
oligomers, while KW2 and KW3 are specific to Aβ40 fibrils (K. Wieligmann, unpublished
data).
Accumulating evidence indicates that Aβ conformers, particularly oligomers, cause
Alzheimer’s disease. Understanding the mode of action of KW domains may help clarify
the structural differences between Aβ aggregates. In the future, this knowledge may facilitate
design of disease modifying strategies. The binding characteristics of KW1, KW2, and KW3
domains will be considered in further sections of this dissertation.
Aβ40 oligomers are not the only toxic spherical conformers involved in neurodegenera-
tion. Pathogenic relevance of Aβ42 oligomers is widely documented (e.g., Roher et al. 1996,
Bernstein et al. 2009, Upadhaya et al. 2011). However, VHH domains specific to Aβ42
oligomers are lacking. Therefore, I attempted to select a VHH domain specific to Aβ42
oligomers in the course of my project.
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1.8 Aims
Aβ peptide aggregation plays an important role in Alzheimer’s disease. The exact
assembly mechanism of Aβ, as well as the structure of the involved Aβ aggregates, is not fully
understood. Accumulating evidence indicates that Aβ conformers, particularly oligomers, are
the pathological agent in Alzheimer’s disease. Therefore, highly specific antibodies capable
of detecting, eliminating, or neutralising toxic Aβ aggregates would be extremely useful in
AD diagnostics and therapy.
The aim of this thesis is to elucidate the mechanism of Aβ-antibody recognition by
analysing the mode of action of selected VHH antibodies. To meet this aim, and to provide
further information on the intricate structure of Aβ aggregates, I will study conformation-
specific antibodies generated by means of phage display from a library of camelid VHH
domains.
I will devise a method of selection for a VHH antibody directed against Aβ42 oligomers.
Such an antibody will potentially be used to discriminate between different types of oligomers;
it may also reveal some potential to alleviate Aβ-mediated neurotoxicity.
Furthermore, I aim to resolve the molecular basis of fibril binding by the existing VHH
antibody domains. To identify the fibril-binding properties of VHH antibodies, B10, KW2
and KW3 antibodies will be analysed with a set of biochemical and biophysical methods. I
will also characterise the KW1 antibody fragment to determine whether its epitope is specific
to a certain oligomer type (e.g., Aβ40 or Aβ42). Molecular characterisation of Aβ specific
binders will enable a comparison of their modes of action, and will supply information about
surface structure of their respective Aβ ligands.
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Chapter 2
Materials and methods
2.1 Basic microbiological solutions and reagents
E. coli cells were cultivated in LB or 2xYT liquid media. Propagation of the plasmids
in E. coli cells was performed in 2xYT medium. Solid plate E. coli cell cultures were grown
on 2% LB agar or 1.5% LB agar (Petri plates). When necessary antibiotics were added,
as selection markers. Kanamycin (30 µg/ml) was used for E. coli cells infected with M13
helper phages; tetracycline (15 µg/ml) for E. coli XL-1 Blue growth, ampicillin (100 µg/ml)
for growth of E. coli cells transformed with p41_6His vector or chloramphenicol (30 µg/ml)
for growth of E. coli cells transformed with ptetpA6H vector. SOC medium was used for the
transformation of E. coli cells.
TB broth was used for the cultivation and protein expression of E. coli RV308 carrying the
plasmids: ptetpA6H_B10glu and ptetpA6H_B10scr. Expression of the remaining antibody
domains (i.e., B10, B10AP, KW1, KW1AP, KW2, KW2AP, KW3, KW3AP) was performed
in M9minimal media, supplemented with trace elements. Additionally, thiamine (vitamin B1)
was supplemented for growth of E. coli RV308 in M9 minimal medium. Detailed components
of particular media are listed in Table 2.1.
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Table 2.1. Microbiological media and their application
Medium Medium components (per 1 L) Application
LB 10 g tryptone, 5 g yeast extract, 10 g NaCl E. coli growth
LB-agar 10 g tryptone, 5 g yeast extract, 10 g NaCl,
15 or 20 g agar
E. coli growth
2×YT 16 g peptone, 10 g yeast extract, 5 g NaCl Plasmid and phage propagation
TB 12 g peptone, 24 g yeast extract, 72 mM K2HPO4,
17 mM KH2PO4
Plasmid propagation and
protein expression in E. coli
SOB 20 g peptone, 5 g yeast extract, 10 mM NaCl,
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4
Preparation of E. coli
competent cells
SOC 20 g peptone, 5 g yeast extract, 10 mM NaCl,
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4,
20 mM glucose
Plasmid transformation and
growth of E. coli
M9 8.6 g Na2HPO4·12H2O, 0.5 g NaCl, 3 g KH2PO4,
1 g NH4Cl, 10 ml Fe-citrate (0.023 M), 0.1 ml EDTA
(0.2 M), 0.1 ml CoCl2·6H2O (0.1 M), 0.1 ml
MnCl2·4H2O (0.75 M), 0.1 ml CuCl2·4H2O (0.1 M),
0.1 ml H3BO3 (0.5 M), 0.1 ml Na2MoO4·2H2O (0.1 M),
2ml Zn(CH3COO)2·2H2O (0.018 M), after autoclaving
added: 5 ml MgSO4 (1M), 20 ml glucose (2.5 M)
High yield protein expression
in E. coli
2.2 Strains, plasmids and oligonucleotides
E. coli strains and phages used for phage display and protein expression are listed in
Table 2.2. Relevant plasmids are shown in Table 2.3.
Table 2.2. Escherichia coli strains and phages
Strain Genotype Source
K12-TG1 supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM)5, (rK–mK–)
F’ [traD36 proAB+ lacIq lacZ∆M15]
Stratagene
K12-RV308 lac74, galIS II::OP308, strA ATCC 31608
K12-XL1-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44
F’[ ::Tn10 proAB+ lacIq ∆(lacZ)M15] hsdR17(rK– mK+)
Stratagene
BL21(DE3) F-, dcm, ompT, hsdSB(rB– mB–), gal λ(DE3),
[pLysS Camr]
Novagen
K12-ER2738 F’proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10(TetR)/fhuA2
glnV ∆(lac-proAB) ∆(hsdS-mcrB)5 [r–kmk–McrBC–]
New England Biolab
M13KE phages M13mp19 derivative, male-specific coliphage,
peptide display as a fusion with pIII
New England Biolab
VCSM13 Helper Phage, derived from M13-K07 mutant, KanR Stratagene
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Table 2.3. Plasmids
Plasmid Expressed construct Reference
pAK 200 phagemid, VHH domains fused to gene III for pre-
sentation on M13 surface, CmR
Plückthun et al. (1996)
p41_6His monovalent VHH domains, PelB signal sequence,
AmpR, TetR
Plückthun et al. (1996)
p41_B10_6His B10 VHH domain, AmpR Habicht et al. (2007)
p41_KW1_6His KW1 VHH domain, AmpR this study
p41_KW2_6His KW2 VHH domain, AmpR this study
p41_KW3_6His KW3 VHH domain, AmpR this study
ptetpA6H bivalent VHH domains as PhoA fusion, PelB signal
sequence, CmR, TetR
Plückthun et al. (1996)
ptet_B10_pA6H B10 AP VHH domain, CmR Habicht et al. (2007)
ptet_KW1_pA6H KW1AP VHH domain, CmR this study
ptet_KW2_pA6H KW2AP VHH domain, CmR this study
ptet_KW3_pA6H KW3AP VHH domain, CmR this study
ptet_B10glu_pA6H B10glu_AP VHH domain, CmR this study
ptet_B10scr_pA6H B10scr_AP VHH domain, CmR this study
Table 2.4 lists the oligonucleotides used in the mutation of ‘amber’ codon in KW2 and
KW3 antibody domains.
Table 2.4. Oligonucleotides used for the replacement of ‘amber’ mutation
Oligonucleotide Sequence 5’ ! 3’
KW3mut_fw CTTTAGCGGTCGTCAAACTTGGTGGTTTC
KW3mut_bw GAAACCACCAAGTTTGACGACCGCTAAAG
KW2mut_fw GATTAATGTGGTTACTCAACGGACCTATTATGCG
KW2mut_bw CGCATAATAGGTCCGTTGAGTAACCACATTAATC
Sfi_fw CGCATTTCTAGATAACGAGGGCAAATCATGAAATACC
Sfi_bw GGTTTTCCAGAACAGGCATTTCCGG
‘bw’: backward primer; ‘fw’: forward primer; oligonucleotides were provided by MWG Biotech
2.3 Standard microbiological and biochemical techniques
2.3.1 Isolation of DNA and preparation of agarose gel
DNA plasmid was isolated from E. coli cells with QIAprep Spin Miniprep Kit (Qiagen),
according to the manufacturer instructions. DNA from the M13 phages was isolated fol-
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lowing the protocol provided by the manufacturer (New England Biolab). Concentration
and purity of DNA was measured with NanoDrop (Thermo Scientific). DNA fragments
were electrophoretically separated on 1% agarose gel and subsequently stained with ethidium
bromide. Subsequently, they were analysed with the gel imaging and documentation system
(Bio Imaging System, Chemi Genius2, Syngene). DNA fragments were extracted from the
agarose gel with QIAquick Gel Extraction Kit (Qiagen).
2.3.2 Cloning, ligation and transformation
Isolated DNA plasmid was processed by digestion with SfiI restriction enzyme purchased
from New England Biolabs GmbH. Digested DNA fragments were extracted from the agarose
gel and inserted to the expression plasmids with T4 DNA Ligase (JenaBioscience, Germany).
Ligated constructs were transformed to chemically competent E. coli cells. Competent E. coli
cells were prepared following the Hanahan (1983) protocol. In brief, 150 ng of DNA was
transformed to 200 µl chemically competent E. coli and incubated on ice for 30 min. Next,
E. coli cells were subjected to a heat shock (42 ◦C) for 2 min, and afterwards 1 ml of SOC-
medium was added. After 1 h incubation at 37 ◦C with vigourous shaking (600 rpm), E. coli
cells were plated on 1.5% LB-agar and incubated overnight at 37 ◦C.
2.3.3 Protein expression in E. coli cells
VHH antibody domains were expressed in the periplasm of E. coli RV308 or E. coli
BL21(DE3) by high cell density fermentation under non-limited growth conditions (Horn
et al. 1996). Initially, E. coli cells from a glycerine stock were inoculated to shaking flask
M9-medium cultures. In order to remove all traces of complex media and adopt E. coli
cells to growth in the minimal media, two pre-cultures were cultivated at 26 ◦C, until OD550
∼2.0. Next, pre-cultures were used for inoculation of 400 ml culture medium in the Sixfors
fermenter (Infors AG, Switzerland) to the start OD550 ∼0.2. Protein expression was triggered
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), when the E. coli cells reached
OD550 ∼60. After IPTG induction culture was growing for additional 4 h, reaching a final
OD550 ∼100. Owing to the unlimited conditions for growth (constant supply of nutrients), the
E. coli cell culture yielded 100 g of fresh weight per 400 ml. In case of periplasmic expression,
dry weigh constitutes ∼20% of fresh weight. Of that, half are proteins, and 2–4% comprise
recombinant antibody domains. The total yield of pure antibody domains from the 400 ml
E. coli culture broth equals approximately 40–80 mg. E. coli cell pellet was harvested by
centrifugation (20 min, 4 ◦C, 6,500 g; Beckman centrifuge Avanti J-20 XP, rotor JLA 8.1000)
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and stored at –80 ◦C.
2.3.4 SDS-PAGE and Western blot analyses
To test the expression level of proteins, double sample aliquots were withdrawn during
the fermentation process. Two samples were taken from each time point (0 h sample – before
IPTG induction, 2 h and 4 h samples – after IPTG induction), six in total. Subsequently,
they were tested with SDS-PAGE and Western blot (WB). All samples from the fermentation
were centrifuged (2 min, room temperature (RT), 14,000g; Centrifuge 5415C, Eppendorf),
resuspended in 20 µl of H2O and stored overnight in –30 ◦C. Next day, samples were heated
for 20 min in 70 ◦C, mixed with 4×NuPAGE lithium dodecyl sulfate (LDS) Sample Buffer
(Invitrogen) and applied on the NuPAGE 4–12% Bis-Tris precast polyacrylamide gel (Invitro-
gen) with the protein standard (SeeBlue Plus2, Invitrogen). Electrophoresis was carried out in
NuPAGE 2-(N-morpholino) ethanesulfonic acid (MES) running buffer (Invitrogen) at 180 V
for approximately 35 min. When the run was completed, gel was cut into half. Half of the gel
with 3 samples was further processed with WB. Remaining half was stained with Coomassie
Brilliant Blue R250, followed by incubation in the destaining solution (Table 2.5).
Table 2.5. Solutions for protein detection after SDS-PAGE
Solution Composition
Coomassie Blue 0.25% (v/v) Coomassie Brilliant Blue R250,
10% (v/v) acetic acid, 30% (v/v) ethanol
Destaining buffer 10% (v/v) acetic acid, 20% (v/v) ethanol
For the WB analysis gel was electrophoretically transferred via semi-dry blotting to
polyvinylidene fluoride (PVDF) membrane, using the WB buffer (Table 2.6). Next, the
membrane was blocked with 2% bovine serum albumin (BSA) in tris-buffered saline (TBS)
for 1 h, washed three times with the TBS, containing 0.1% tween (TBST). Subsequent
0.5 h incubation with the primary antibody (mouse, anti-[His]6 tag antibody, Qiagen), was
followed by three times for 5 min washing with TBST and three times for 5 min washing with
TBS. Next, membrane was incubated for 0.5 h with secondary antibody (goat, anti-mouse
IgG (Fc), alkaline phosphatase conjugated, Thermo Fisher Scientific) and washed six times
as described previously. Colorimetric detection was performed with PNPP (p-nitrophenyl
phosphate, disodium salt), substrate (Pierce) for AP.
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Table 2.6. Buffers for WB
Buffer Composition of the buffer
WB buffer 25 mM Tris, 0.2 M glycine, in 20% (v/v) ethanol, pH 7.4
TBST 150 mM NaCl, 50 mM Tris-HCl, 0.1% (v/v) Tween-20, pH 7.4
TBS 150 mM NaCl, 50 mM Tris-HCl, pH 7.4
2.3.5 Purification of the VHH-domains (monovalent and AP-fusion)
40 g of the frozen E. coli cell pellet was resuspended in the disruption buffer (Table 2.7)
and filtrated. Next, E. coli cells were disrupted in a cell homogeniser (Emulsiflex-C550,
Avestin). Afterwards, 0.5% Tween was added and pH adjusted to 8.0 with 1 M NaOH.
After centrifugation for 90 min at 30,000 g in 4 ◦C (BECKMAN centrifuge Avanti J-20 XP,
rotor JA-14) the supernatant was filtered consecutively through 1.2 µm and 0.45 µm filtration
membranes.
Protein purification was performed in two chromatography steps on an Äkta Explorer
901 system (GE Healthcare). Purification of the [His]6 tag monovalent antibody domains
was performed by an immobilised metal ion affinity chromatography (IMAC), followed by a
reversed phase chromatography (RPC). 50 ml NiNTA (26 XK, GE Healthcare, Germany) and
20 ml Source-RPC (HR 16, GE Healthcare, Germany) columns were applied. Before loading
the bacteria crude extract, columns were equilibrated with the washing buffers (Table 2.7 and
2.8). For the NiNTA column a step gradient of the elution buffer was applied. This included
increasing concentrations of elution buffer: 7%–washing step, 40%–elution and 100%–final
washing step. For the Source-RPC column a linear gradient of the elution buffer was applied.
Collected fractions were frozen in liquid nitrogen and lyophilised (Christ, Alpha 1–4). Purity
level of the proteins was checked with the SDS-PAGE and the protein concentration was
measured. Pure fractions containing VHH antibody fragments were stored in –30 ◦C.
Table 2.7. Buffers for IMAC
Buffer Composition of the buffer
Disruption buffer 50 mM sodium phosphate, 1 M NaCl, 20 mM imidazol, pH 8
Wash buffer 50 mM sodium phosphate, 300 mM NaCl, 20 mM imidazol, pH 8
Elution buffer 50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazol, pH 8
Purification of the [His]6 antibody domains fused with AP, was carried out with IMAC
and ion exchange chromatography (IEC). For the IMAC, a 50 ml NiNTA column was used
and a three-step gradient (10%, 40% and 100%) of elution buffer was applied. A QSepharose
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Table 2.8. Buffers for RPC
Buffer Composition of the buffer
Wash buffer H2O with 0.1% trifluoroacetic acid (TFA)
Elution buffer Acetonitril with 0.1% TFA
column (anion exchanger, 16 XK, GE Healthcare, Germany) was used for the IEC; a linear
gradient of elution buffer was applied. Buffers for IEC purification of the particular VHH
domain differed slightly and their content is listed in Table 2.9. Purity of the proteins was
checked with the SDS-PAGE, protein concentration was measured and pure fractions were
frozen in liquid nitrogen and stored in –30 ◦C.
Table 2.9. Buffers for IEC
VHH domain Wash buffer Elution buffer
B10AP 20 mM Tris, pH 8.2 20 mM Tris, 2 M NaCl, pH 8.2
KW1AP 20 mM Tris, pH 7.7 20 mM Tris, 1 M NaCl, pH 7.7
KW2AP 20 mM Tris, pH 8 20 mM Tris, 2 M NaCl, pH 8
KW3AP 20 mM Tris, pH 8.3 20 mM Tris, 2 M NaCl, pH 8.3
B10glu_AP 20 mM Tris, pH 7.2 20 mM Tris, 0.5 M NaCl, pH 7.2
B10scr_AP 20 mM Tris, pH 8.2 20 mM Tris, 2 M NaCl, pH 8.2
An additional purification step was performed for the purification of the B10glu_AP. The
purest fractions after NiNTA and QSepharose purification were concentrated with size exclu-
sion filters (Amicon Ultra, Ultracel-50 K, Millipore) following the manufacturer instructions.
2.3.6 Determination of protein size, purity, and concentration of the purified proteins
The purified proteins were thermally denatured by heating for five minutes in 95 ◦C. Next,
the size, and the level of purity was tested with SDS-PAGE, as described in section 2.3.4.
Determination of the protein concentration in the solution was carried out according to method
described by Gill and von Hippel (1989). Before the absorption measurement, the proteins
were denatured with 6 M guanidine hydrochloride and 20 mM sodium phosphate (pH 6.5).
The molar extinction coefficient was calculated based on the number of tyrosines, tryptophans
and cysteines in the protein sequence (Gill and von Hippel 1989).
Alternatively, the concentration of the protein was measured with Bradford assay (Brad-
ford 1976), which requires an acidic solution of Coomassie-dye reagent (Coomassie Brilliant
Blue G-250, Bio-Rad). This dye shifts protein absorbance from 465 nm to 595 nm; the reagent
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changes the colour from brown to blue upon binding with a protein. BSAwas used as a protein
standard for the preparation of a calibration curve. Absorption at wavelengths of 280 nm and
595 nm was measured with a UV-Vis spectrophotometer (Bio Photometer, Eppendorf).
2.3.7 Enzyme-linked immunosorbent assay (ELISA)
Streptavidin coated plates (Reacti-Bind Streptavidin High Binding Capacity Coated 96-
well plates, Pierce) were used for ELISA. Prior to immobilisation of biotinylated target
proteins, plates were washed three times for 5 min with TBST buffer containing 0.2% (v/v)
of BSA. Next, 100 µl of biotinylated Aβ40 fibrils were applied per well, and agitated at 150
rpm for 1 h. Subsequently, two five-minute-long washes with TBST were performed. They
were followed by blocking the plate with 2% BSA in the TBST buffer. Plate was agitated at
300 rpm for 1 h at RT, or alternatively, left overnight at 4 ◦C. Next, the plate was washed three
times with TBST. 100 µl of either 0.5 µg/ml B10AP, B10glu_AP, or B10scr_AP were added
per well. 1 h incubation with agitation at 150 rpm was followed by six washing steps (three
times for five minutes with TBST, and three times for five minutes with TBS). To analyse the
binding between antibodies and fibrils a colorimetric reaction was performed. The plate was
incubated with gentle agitation (150 rpm) for 0.5 h with a substrate for AP, i.e., PNPP. The
reaction was stopped by addition of 50 µl 2 M NaOH per well. The absorption was measured
at 405 nm, using BMG FLUOstar OPTIMA plate reader. A blank solution (TBS buffer) was
used as reference.
2.3.8 Spot blot
Nitrocellulose membranes (0.1 µm; Protran, Whatmann) were used for the spot blot
assays. 30 µl of amyloid fibrils or oligomers were spotted in triplicates on two membranes.
One membrane was subsequently incubated for 1 h in a 2% Ponceau S solution (Sigma-
Aldrich) and washed with H2O. Ponceau S staining was used to confirm equal protein load,
and for Aβ40 oligomers and Aβ40 fibrils was set to 100% (as a full staining reference). The
second membrane was blocked with a 2% BSA solution in TBST buffer for 1 h. Next, the
membrane was washed two times for five minutes with TBST, followed by 1 h incubation of
the membrane with antibody fragments fused with alkaline phosphatase. In case of amyloid
fibrils spotted on the membrane B10AP (0.5 µg/ml), B10scr_AP (0.5 µg/ml), and B10glu_AP
(0.5 µg/ml) in TBST buffer were used. KW1AP (1 µg/ml) in TBST buffer was used in
case of oligomers spotted on the membrane. Next, membrane was washed three times for
five minutes with the TBST buffer, and three times for five minutes with the TBS buffer.
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Colorimetric reaction was developed with nitro-blue tetrazolium chloride and 5-bromo-4-
chloro-3’-indolyphosphate p-toluidine salt (NBT/BCIP, Roche), which constitutes a substrate
for AP. Densitometric quantification of the color intensity was performed with TotalLab
software.
2.4 Selection of VHH antibody from the camelid phage library
2.4.1 Biotinylation and immobilisation of the target
B10AP was biotinylated prior to be used as an antigen for the phage display with
commercial peptide libraries. 7 µMB10AP was incubated for 1 h, at RT with 15 µM of Sulfo-
NHS-LC biotin (Pierce) in 10 mMHepes buffer (pH 7.4). Reaction was quenched by addition
of 10 mM Tris-HCl, pH 8.5 (5% v/v). To remove non-reacting biotin reagent, biotinylation
reaction mixture was dialysed against 10 mM Hepes buffer, 150 mMNaCl (pH 7.4). Presence
of one molecule of biotin per one B10AP molecule was confirmed with mass spectrometry.
Another target for the phage display, biotinylated Aβ42 oligomers were prepared by mixing of
N-biotinylated synthetic Aβ42 peptide (MoBiTec) with unbiotinylated synthetic Aβ42 peptide
(Bachem) in a 1:10 molar ratio. Aβ42 oligomers were prepared according to preparation
I and IV, as described in section 2.6.2. Prior to phage selection procedures, biotinylated
proteins (B10AP or Aβ42 oligomers) were immobilised on streptavidin-coated magnetic
beads (Dynabeads-280M Streptavidin, Invitrogen).
2.4.2 Phage display procedure
The recombinant, fully synthetic antibody phage library used for the VHH selection
was generated in HKI by G. Habicht and M. Siegemund (Habicht 2002). Construction of
the library was based on Camelidae VHH antibody fragments. The diversity of the phage
library equalled 6 × 108; the library consisted of 1011 clones. VHH antibody fragments were
displayed on the surface of the M13 phage as a fusion protein with pIII phage coat protein.
HKI antibody library was read out by phage display. Phage display procedure includes several
consecutive and repeatable steps.
First, biotinylated Aβ42 oligomers were immobilised on the streptavidin coated magnetic
beads in panning buffer (Table 2.10) and agitated (500 rpm) for 1 h. Second, streptavidin
beads with the immobilised antigen were blocked by 1 h incubation with 2% BSA, followed
by washing with panning buffer and addition of BSA-blocked library phages, displaying VHH
domains. Phages were incubated with the target for 1 h at RT, with shaking (500 rpm).
Unbound phages were pulled out from the solution during 20 washing steps (ten washes with
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Table 2.10. Buffers and solutions for phage display selection
Solution Composition
Panning buffer 10 mM Hepes, 150 mM NaCl, pH 7.4
Panning buffer with Tween 10 mM Hepes, 150 mM NaCl, 0.05% Tween, pH 7.4
Elution buffer 0.1 M HCl, titration to pH 2.2 by adding glycine
Neutralization buffer 2 M Tris
Precipitation solution 17% PEG 6000, 3.3 M NaCl, 1 mM EDTA
panning buffer containing 0.05% Tween, followed by ten washes with the panning buffer
only). Elution of phages bound to the target, was performed by 2 min incubation with the
HCl/Glycine (pH 2.2) solution (Table 2.10).
Eluted phages were transferred to the new tube and neutralised with 2 M Tris. Phage
solution was subsequently used for transfection of XL1-Blue E. coli cells, which were grown
to OD550 ∼0.6. Transfected cells were incubated, without agitation for 0.5 h in 37 ◦C and
plated on the 2% LB agar plates, containing chloramphenicol as a selection marker. On the
following day, cells were scrubbed from the plates. Phages were amplified in an E. coli liquid
culture, in presence of M13 helper phages. Expression of the phage proteins was induced
with the 1 mM of IPTG. To recover the enriched phages from the XL1-Blue E. coli cells,
phages were precipitated. First, overnight E. coli culture was cooled on ice for 30 min,
centrifuged (20 min, 7,000 rpm, 4 ◦C) and the phage containing supernatant transferred to
a sterile 50 ml falcon tubes, filled with 25 ml ice-cold precipitation solution (Table 2.10).
Phages were precipitated by incubation with precipitation solution for 1 h , at 4 ◦C, followed
by centrifugation (20 min, 7,000 rpm, 4 ◦C). Precipitated phages along the side of the tube,
were resuspended in the 17 ml of the panning buffer and again precipitated by addition of 20
ml cold PEG. 1 h incubation on ice, was followed by centrifugation (20 min, 7,000 rpm, 4
◦C) and final resuspension of the concentrated phages (visible precipitate on the side of the
tube) in 4 ml panning buffer. Titer of the precipitated phages was determined as followed.
Dilution series of the phages (from 103 to 1014) were performed and transfected of the E. coli
cells in the growing phase (OD550 ∼0.5–0.7). Transfected E. coli cells were incubated for
0.5 h without agitation, at 37 ◦C and subsequently plated on the 1.5% LB small agar plates,
containing chloramphenicol as selection marker. Next, plates were incubated overnight at 37
◦C. Phage titer was calculated based on the number of E. coli colonies, which appeared on the
plates.
Precipitated library phages were used for the next selection round. The whole process of
selection, precipitation, and titer determination was performed four times in total. Different
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blocking reagents were used interchangeably between rounds (i.e., 2% BSA and 2% skim
milk, Merck). After four rounds of selection, single phage clones were isolated. For this
purpose, XL-Blue E. coli cells, infected with phages, were diluted and plated on several 1.5%
LB agar plates. The lowest dilution (104–105) allowed the isolation of single colonies. 40
random, single colonies were further amplified; the single phage clones were precipitated, as
described previously. Single phage clones were subsequently sequenced, or tested for binding
to the target with phage ELISA.
2.4.3 Panning with the peptide library
B10AP, biotinylated and immobilised on streptavidin beads (Dynabeads-280M Strepta-
vidin, Invitrogen), was used as an antigen in the selection with the peptide library. Two
different peptide libraries were used. First, Ph.D.-7 library (New England Biolabs) consisted
of ∼2.8 × 109 M13 phages, displaying a linear heptapeptide on their surface. Second library,
Ph.D.-C7C (New England Biolabs), consisted of ∼2.8 × 109 M13 phages, displaying a
disulphide-constrained, cyclic heptapeptide. Due to the oxidising conditions during the phage
assembly, the disulphide bridge is created; the displayed peptide is presented as a loop on the
phage surface. I performed three rounds of selection with both peptide libraries, following the
protocol provided by manufacturer (New England Biolabs). After three rounds of panning,
the DNA of 43 single clone phages was isolated and sequenced. Two predominant, repeating
DNA sequences emerged. They were translated into amino acid sequences and synthesised
chemically (EMC-microcollections).
2.4.4 Phage ELISA
Phage ELISA was carried out on streptavidin-coated plates (Reacti-Bind Streptavidin
High Binding Capacity Coated 96-well plates, Pierce). The ELISA plate was coated with 100
µl of biotinylated antigen per well (2 µg of Aβ42 oligomers, or 2 µg of B10AP, dissolved in
panning buffer), or with the panning buffer only (negative control). Next, plate was incubated
for 1 h at RT, with shaking at 150 rpm. Prior to the blocking of the antigen with 2% BSA, the
plate was washed twice with the panning buffer, each time for five minutes. Subsequently, the
wells were washed three times for five minutes with the panning buffer, and the single clone
phages were added (100 µl per well). Following, the plates were incubated for 1 h at RT, with
shaking at 150 rpm. Afterward, the plate was washed three times with the panning buffer,
and three times with the panning buffer containing 0.05% Tween. Later, each well received
100 µl of HRP anti-M13 Monoclonal Conjugate (conjugate of horseradish peroxidase with
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mouse anti-M13 monoclonal antibody, GE Healthcare), diluted 1:5,000. In the next step, the
plate was incubated for 1 h; six washing steps followed – three times with the panning buffer
containing 0.05% Tween, and three times with the panning buffer. Finally, 100 µl of ABTS
substrate solution (Roche) was added to each well. The ELISA signal was developed during
the incubation of the plate for 0.5 h. The absorption was measured at 450 nm, using the BMG
FLUOstar OPTIMA plate reader. A blank solution served as reference; it was derived from
an identical procedure, with exclusion of the antigen (panning buffer only).
2.5 SPR analysis
2.5.1 Biotinylation and immobilisation of amyloid aggregates
Aβ40 peptide was biotinylated in a molar ratio 1:1 (biotin : amyloid peptide) with
Sulfo-NHS-LC-Biotin (Pierce). Biotinylation was carried out by 1 h incubation of biotin
and Aβ40 peptide in H2O at RT. The excess of the biotin reagent was removed with RPC
chromatography and biotinylation of Aβ40 peptide was verified with mass spectrometry.
Prior to immobilisation of the biotinylated Aβ40 peptide on the streptavidin (SA) sensor
chip surface (Biacore), disaggregation procedure was performed. 1 mg of Aβ peptide was
dissolved in 2 ml 1:1 mixture of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and trifluoroacetic
acid (TFA). After 4 h of incubation at RT HFIP and TFA were evaporated under steady
stream of nitrogen. The dry peptide was dissolved in 0.15% ammonium hydroxide, vortexed
vigorously and exposed to ultrasonic waves for 1 min and lyophilised. Disaggregated peptide
was stored in –80 ◦C.
For preparation of 1:10 (biotin : peptide) biotinylated Aβ40 oligomers, 0.1 mg of biotiny-
lated Aβ40 peptide was mixed with 0.9 mg of unbiotinylated Aβ40 peptide and resuspended
in 100% HFIP, incubated for 15 min at RT, diluted 1:10 with H2O and further incubated for 15
min. Next, larger aggregates were removed by centrifugation (15 min, 13,000 rpm, RT) and
80% of supernatant containing biotinylated Aβ40 oligomers was withdrawn. Biotinylated
oligomers were immobilised on SA sensor surface (Biacore), which was activated with
NHS/EDC cross-linker (Pierce).
To prepare biotinylated Aβ40 fibrils for the SPR measurements, 1 mg of Aβ40 peptide
was dissolved in 50 mM Na3BO3 buffer (pH 9) and incubated for 1 week at RT. Biotinylation
of the Aβ40 fibrils was performed in 50 mM Na3BO3 buffer (pH 9) with Sulfo-NHS-LC-
Biotin (Pierce) in a molar ratio 1:100 (biotin : Aβ peptide). Biotinylation reaction mixture
was dialysed against 10 mM Hepes buffer (pH 7.4), containing 150 mM NaCl. Biotinylated
Aβ40 fibrils were immobilised on a SA chip (Biacore).
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2.5.2 SPR measurements
Monovalent antibody domains (24 B10 single site mutants, KW2 and KW3) were injected
on a SA chip in a series of concentrations – from 800 nM to 25 nM. Bivalent antibody
domains (B10AP, KW1AP, KW2AP and KW3AP) were injected on the SA sensor in a series
of concentrations – from 200 nM to 6.25 nM. Each antibody concentration was injected
twice. SPR measurements were taken in 10 mM Hepes buffer (pH 7.4), 150 mM NaCl, 3
mM ethylene-diaminetetraacetic acid, 0.005% (v/v) surfactant Tween20 with Biacore 2001.
aKD was calculated based on 1:1 steady state affinity model. SPR measurements of the
B10 antibody domains, in presence of P1 or P2 peptide (Table 2.11) as a competitor, were
performed on the SA sensor under the same conditions as the analysis of the monovalent
VHH.
Table 2.11. Conditions for the competitive SPR analysis
B10 (control) B10 + P1 peptide B10 + P2 peptide
800 400 + 4,000 400 + 4,000
400 400 + 2,000 —
200 400 + 1,000 —
100 400 + 500 —
50 400 + 250 —
25 400 + 125 —
– 400 + 62.5 —
– 400 + 31.25 —
Concentrations (nM) of B10, P1 and P2 peptides taken for SPR
measurements
Molar stoichiometry of KW1-oligomer complexes was calculated based on the SPR
measurements (maximum binding capacity of the oligomer coated sensor surface and the
response level of immobilised Aβ40 oligomers) and the mass of the KW1 and Aβ40.
2.6 Preparation of the amyloid aggregates
2.6.1 Amyloid-like fibrils
Aβ40 fibrils. Recombinant Aβ40 peptide (1 mg/ml, expressed in HKI by U. Knüpfer) was
dissolved in the 50 mM Hepes buffer (pH 7.4), 50 mM NaCl and incubated for 1 week in 37
◦C. Alternatively, 1 mg/ml (230 µM) of synthetic Aβ40 peptide (Bachem) was dissolved in
50 mM Na3BO3 buffer (pH 9) and incubated for 1 week at RT.
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Aβ42 fibrils. Synthetic Aβ42 peptide (0.5 mg/ml, Bachem) was dissolved in the 50 mM
Na3BO3 buffer (pH 9) and incubated for 5 days at RT.
Ccβ fibrils. Synthetic Ccβ peptide (1 mg/ml, JPT Peptide Technologies) was dissolved in
the 200 mM sodium phosphate buffer (pH 7.2) and incubated for 1 week at 37 ◦C (Kammerer
et al. 2004).
Calcitonin fibrils. To obtain the calcitonin fibrils, 1.5 mg/ml of the calcitonin (Bachem)
was incubated in 20 mM sodium acetate buffer (pH 7.5) for 1 week at RT (Reches et al. 2002).
Ure2p(10–39). Synthetic Ure2p(10–39) peptide (0.25 mg/ml, JPT Peptide Technologies)
was dissolved in the 10 mM sodium phosphate buffer (pH 7.4). Fibrils formed immediately
as a visible precipitate (Chan et al. 2005).
β2-microglobulin(20–41). Fibrils were obtained by dissolving synthetic β2-microglobulin
(20–41) peptide (JPT Peptide Technologies) at a concentration of 0.25 mg/ml, in the 20%
trifluoroethanol (TFE), 10 mMHCl, 1 mMNaCl buffer (pH 7.5), followed by 1 day incubation
at 25 ◦C (Iwata et al. 2006).
2.6.2 Amyloid oligomers
Preparation I of Aβ40 and Aβ42 oligomers: Aβ peptide (1 mg) was dissolved in 450 µl of
100%HFIP, resuspended by vigourous agitation, incubated for 15 min at RT and subsequently
diluted 1:10 with H2O. After further 15 min incubation, larger aggregates were removed by
centrifugation (15 min, 14,000 g, RT) and 80% of the supernatant containing Aβ oligomers
was withdrawn (according to Habicht et al. 2007).
Preparation II of Aβ40 and Aβ42 oligomers: Aβ oligomers (0.25 mg/ml) from preparation
I were subjected to stirring (using small bar stirrer) in 1.5 ml eppendorf tube containing four
18-gauge needle holes in the cap. This allowed for the slow evaporation of the HFIP and H2O,
and subsequent exposure of spherical oligomers to air-water interface. After 12 h stirring
oligomers solution was transferred to a new tube (adapted from Kayed et al. 2009).
Preparation III of Aβ40 and Aβ42 oligomers: Aβ peptide (0.5 mg) was dissolved in ice-
cold 100% HFIP to 1 mM final peptide concentration, incubated for 1 h at RT and for further
10 min on ice. Next, the HFIP was evaporated by overnight incubation at RT with an open lid.
Subsequently, all traces of the HFIP were removed by drying down the peptide on a SpeedVac
(Savant) for 10 min. Dry peptide was dissolved in 35 µl dimethyl sulfoxide (DMSO), diluted
with 1.13 ml ice-cold F12 medium, without phenol red (Invitrogen) and incubated for 24 h at
5 ◦C. The solution was then centrifuged (14,000 g, 10 min, 5 ◦C) and supernatant containing
oligomers was transferred to the new tube (adapted from Klein 2002).
Preparation IV of Aβ42 oligomers: Aβ42 peptide (1 mg) was dissolved in the 167 µl
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100% HFIP, vigorously mixed and incubated with shaking (400 rpm) overnight at 37 ◦C.
Next, the solution was sonicated for 5 min and HFIP was evaporated on a SpeedVac (Savant).
The dry peptide was resuspended in 5 mM DMSO, followed by two cycles of sonication
and vortexing (20 seconds each). After addition of 400 µM phosphate-buffered saline (PBS)
(20 mM NaH2PO4, 140 mM NaCl, pH 7.4) and 2% (v/v) of SDS, solution was incubated
for 6 h at 37 ◦C, diluted with 3 volumes of H2O and further incubated for 18 h (37 ◦C).
Centrifugation (3,000 g, 20 min, RT) was followed by sample concentration by ultrafiltration
(Amicon Ultra, 30 cut-off, Millipore). To remove SDS, the last step was repeated 3 times and
after each ultrafiltration, the retentate has been resuspended in 4 times diluted PBS (5 mM
NaH2PO4, 35 mM NaCl, pH 7.4). The final solution volume (45 µl concentrated sample)
was centrifuged (10,000 g, 10 min, RT) and supernatant containing preparation IV of Aβ42
oligomers withdrawn. Aliquots were frozen in liquid nitrogen and stored in –80 ◦C for a
couple of months (adapted from Barghorn et al. 2005).
2.7 TEM measurements
The morphology of Aβ aggregates was assessed with TEM. Samples for TEM were
negatively stained with 2% (v/v) uranyl acetate, using a droplet technique. 5 µl of an amyloid
solution with a concentration of 0.1 mg/ml was placed on a formvar coated copper grid (Plano)
and 5 minutes incubated. Next, the grid was washed three times by dropping it in H2O.
Washed grids were submerged into a drop of 2% (v/v) uranyl acetate solution for negative
staining. Specimens were analysed with a Zeiss 902 electron microscope equipped with on a
Orius SC 1000 CCD camera (Gatan) and operated at an acceleration voltage of 80 kV. 50,000×
or 85,000× magnification was used for imaging.
2.8 ATR-FTIR spectroscopy
For ATR-FTIR spectroscopy measurements, Aβ40 oligomers (preparation I and II) were
concentrated to 2 mg/ml with Amicon Ultra-4 centrifugation filters with 30 kDa cut-off
(Millipore). Aβ42 oligomers (preparation I and II) were concentrated by centrifugation (15
min, 14,000 rpm, RT) to 2 mg/ml. Final preparations of all oligomers were examined with
TEM, to confirm whether the sample was free from fibrillar aggregates. Immediately prior to
analysis residual HFIP was evaporated under steady stream of N2 for 30 min. Infrared spectra
of oligomers were recorded in water. All spectra were acquired on a Bruker Tensor-27 FTIR
instrument equipped with a BIO-ATR-II cell and a photovoltaic LN-MCT detector cooled
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with liquid nitrogen. The final spectra are average of the 64 scans after buffer subtraction.
Spectra were collected at RT with an aperture of 6 mm and at a spectral resolution of 4 cm–1.
The resulting spectra were processed by atmospheric compensation.
2.9 ThT fluorescent measurements
ThT spectra of amyloid fibrils and aggregating Aβ peptide were recorded at RT, with a
fluorimeter (RF-5301 PC, Shimadzu), using an excitation wavelength of 482 nm. Measure-
ments were performed in 50 mM Hepes buffer (pH 7.4) with 50 mM NaCl, in a 5-mm path
length cuvette (Hellma). Every sample consisted of 20 µM ThT (Sigma) solution and 5 µM
of Aβ fibrils, or 5 µM other Aβ aggregates. Aliquots of Aβ aggregates for ThT fluorescent
measurements have been withdrawn every hour during the 24 h Aβ incubation assay.
2.10 Disaggregation assay
50 µM of Aβ40 fibrils were incubated with or without 5 µM of KW1AP in 50 mM Hepes
(pH 7.4), 50 mM NaCl for 1 week at 37 ◦C. Next, samples were centrifuged (14,000 rpm, 30
min, RT) and fractionated for supernatant and pellet. The pellet fractions was resuspended in
the original buffer volume. An aliquot of the sample before centrifugation, supernatant and
pellet fraction were analysed with SDS-PAGE and TEM.
2.11 Aβ peptide incubation assay
0.5 mg/ml of recombinant Aβ40 peptide was incubated in 50 mM Hepes (pH 7.4), 50 mM
NaCl for 24 h at 37 ◦C, without shaking. Every hour three equal-volume-aliquots of the Aβ40
sample were withdrawn, tested for binding to KW1AP with spot blot, analysed with TEM,
and ThT fluorescence.
2.12 Site directed mutagenesis of KW2 and KW3
The TAG ‘amber’ stop codons from the DNA sequences of KW2 and KW3 were replaced
into CAA triplet, coding for glutamine. Replacement of the stop codon was performed with
a two-step PCR by using the QuickChange II XL Site Directed Mutagenese Kit (QiaGen),
following the manufacturer instructions. Briefly, two different primer sets (Table 2.4) were
used to introduce the point mutation into the DNA sequence of KW2 and KW3. In the
first PCR cycle the point mutations were introduced and two DNA fragments for each
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VHH domain generated. The second DNA cycle was performed to assemble the two DNA
fragments (Figure 2.1). Proper introduction of the point mutation was confirmed by DNA
sequencing. DNA of KW2 and KW3 domains without stop codons were subsequently cloned
into p41_6His and ptetpA6H vectors and used for transformation of competent E. coli RV308
cells.
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Figure 2.1. Replacement of the ‘am-
ber’ codon in KW2 and KW3 DNA
sequences. Two different primer sets
were used in two rounds of PCR. A
and B external primers (black arrows)
cover whole VHH fragments and C
and D internal primers (orange arrows)
insert the CAA codon in place of am-
ber codon. The primers A-Dwere used
for the first PCR cycle. It resulted
in generation of two DNA fragments
void of amber codon. Second PCRwas
performed only with external primers
(A,B) to assemble two shorter DNA
fragments, which resulted in DNA
coding for VHH without stop codons
(a). PCR fragments are visualised on
a DNA agarose gel. (1) and (2): AD
and CB fragments of KW2 sequence;
(3) and (4) AD and CB fragments of
KW3 sequence; (5) and (6) assembled
DNA sequences of KW2 and KW3 re-
spectively, containing CAA glutamine
codons (b).
2.13 Generation of B10 variants
Two variants of the B10 antibody fragments – B10glu and B10scr, were generated from
the synthetic DNA fragments (GeneArt). The synthetic DNA fragments coding for B10glu
and B10scr were cloned into ptetpA6H expression vectors, transformed to competent E. coli
BL21(DE3) cells and expressed as a fusion protein with alkaline phosphatase. Large scale ex-
pression of B10glu_AP and B10scr_AP was performed in the periplasm of E. coli BL21(DE3)
cells, in 400 ml vessels in TBmedium. Purification of B10scr_AP and B10glu_APwas carried
out as described in section 2.3.5.
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Chapter 3
Results
3.1 Selection of an antibody fragment against Aβ42 oligomers
Oligomers are thought to constitute the most toxic Aβ species in the brain (Walsh and
Selkoe 2004). KW1, an antibody fragment selected previously, is conformationally specific to
Aβ40 oligomers, but does not recognise Aβ42 oligomers (Morgado et al. 2012). I attempted to
select an antibody fragment directed against Aβ42 oligomers. Selection of such an antibody
would enable the comparisons of the two oligomeric binders, and provide the information
about the surface structure of prefibrillar Aβ aggregates.
3.1.1 Preparation and structural features of Aβ42 oligomers
I used the phage display technique to select an antibody against Aβ42 oligomers. For the
purpose of the phage display selection, I prepared and characterised two variants of oligomeric
Aβ42 aggregates. These two variants of Aβ42 oligomers are referred to as preparation I and
preparation IV. Both oligomeric entities were presented as antigens in the VHH antibody
selection process. The two antigens were used to increase the diversity presented structures,
thus increasing the probability of a successful selection of an antibody fragment specific to at
least one of the Aβ42 conformers.
Two different protocols were implemented to generate these oligomers. Preparation I
of Aβ42 oligomers was obtained by dissolving Aβ42 peptide in HFIP. This organic solvent
was shown to break down the β-sheet structure, disrupt hydrophobic forces in amyloid
preparations, and in result prevent the aggregation of Aβ peptide into fibrils (Barghorn et al.
2005, Stine Jr et al. 2003). After 15 minutes of incubation, the solution was diluted 1:10 with
H2O, and incubated for further 15 minutes. Subsequently, the sample was centrifuged; the
supernatant containing the oligomers was withdrawn (Kayed et al. 2003). Prepared entities
were structurally analysed with TEM. An aliquot of the sample was spotted on carbon-copper
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grids, and negatively stained with uranyl acetate. TEM images revealed small spherical
species 5–15 nm diameter; fibrils could not be detected in this sample by negative staining
(Figure 3.1a).
Preparation IV of Aβ42 oligomers was obtained by dissolving 1 mg of Aβ42 peptide
in 1 ml of 100% HFIP. Subsequent evaporation of HFIP was followed by resuspention of
the peptide in DMSO, sonication, and dilution with PBS to 400 µM. Next, the sample was
incubated for 6 h in presence of 0.2% SDS, diluted with H2O, and incubated for additional
18 h. Subsequently, the sample was centrifuged and concentrated by ultrafiltration; the
supernatant containing the concentrated Aβ42 species (ca. 5 mg/ml) in PBS was withdrawn
(Barghorn et al. 2005). Resultant Aβ42 oligomers were determined with TEM as non-fibrillar
particles with diameters of 7–20 nm (Figure 3.1a).
To test their stability, the prepared oligomers were incubated at different temperatures for
a certain time. Aβ42 oligomers (preparation I) were incubated in 4 ◦C in presence of 10%
HFIP for several weeks. Their stability was tested with TEM (Figure 3.1b). Two-weeks-old
samples were full of the spherical aggregates and free from fibrils, but after that time, some
fibrillar aggregates started to appear. Aβ42 oligomers (preparation IV) were stable and free
from fibrils for 3 days after incubation in PBS at 4 ◦C (Figure 3.1b). Preparation IV of Aβ42
oligomers was aliquoted, frozen in liquid nitrogen and stored at –80 ◦C for several weeks.
Prior to further analyses, preparation IV was thawed and diluted in PBS.
Figure 3.1. TEM images of Aβ42 oligomers visualised by negative staining. (a) Preparation I of
Aβ42 oligomers: fresh and incubated in 10% HFIP at 4 ◦C for 2 weeks; (b) Preparation IV of Aβ42
oligomers: fresh and incubated in PBS buffer at 4 ◦C for 3 days.
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3.1.2 Selection of the VHH domain against Aβ42 oligomers
For the selection of the binders targeting Aβ42 oligomeric states, a recombinant VHH
phage library generated at the HKI was used. In order to facilitate binding to streptavidin-
coated paramagnetic beads, both preparations of Aβ42 oligomers had to be biotinylated prior
to the selection procedure. Biotinylation of oligomers was achieved by mixing N-biotinylated
synthetic Aβ42 peptide with unbiotinylated Aβ42 peptide in a 1:10 molar ratio. Subsequently,
the biotinylated Aβ42 oligomers (preparation I and IV) were prepared according to the
procedures described in section 2.6.2.
Two different selection strategies were tested in order to generate a highly specific binder
(Table 3.1). Both selections were carried out in presence of a competitor. A competitive
selection involves usage of two antigens, of which one is immobilised and serves as a target,
while the second is dissolved in the solution. Cross-reacting with the competitor, the binders
are eliminated together with unbound phages during the panning procedure. Panning is
defined as the incubation of the library with the target, followed by washing away of the
unbound phages, and elution of the bound phages. Alternatively, competitive conditions
are obtained by the immobilisation of the mock antigen, followed by a preselection panning
round. Preselection is the incubation of the library with the mock target; it enables the disposal
of the cross-reacting binders. Unbound phages are withdrawn, and are subsequently used in
the actual selection. Selection under competitive conditions provides some unique advantages
(e.g., elimination of cross-reactivity, high selectivity of the binders), which would not be
possible to obtain with vaccination.
To remove unspecific binders, each selection strategy included two blocking reagents, i.e.,
skim milk and BSA. Those blocking reagents were used alternately throughout the panning
Table 3.1. Comparison of the first and the second selection strategy
Selection Target for Competitor in Target [µg] Number of Phage
strategy preselection the solution colonies titer
First
Aβ40
Absent
Aβ42 I1.0 × 106 I2 × 1011
oligomers oligomers II1.2 × 104 II4 × 1011
(30 µg) (preparation IV) III1.0 × 105 III6 × 1010
I20; II10; III5; IV1 IV2.5 × 105 IVsingle colony
Second
Aβ42 Aβ42 Aβ42 I1.0 × 106 I1 × 1011
fibrils peptide oligomers II1.0 × 104 II1 × 1010
(30 µg) I cycle: 150 µg (preparation I) III6.5 × 105 III1 × 1011
III cycle: 250 µg I25; II20; III15, IV10 IV1.0 × 105 IVsingle colony
Superscript Roman numerals indicate the order of the panning cycles
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cycles. The excess of blocking reagents in the solution excluded the unspecific binders:
phages displaying VHH unspecific to the target bound either to skim milk or to BSA, and
were subsequently washed away.
A preselection round was performed as an initial step of both selection strategies. The
purpose of preselection was to exclude the cross-reacting binders from the library, because
they bind to different Aβ conformers instead of the intended target. For the preselection,
Aβ40 oligomers in the first selection strategy, and Aβ42 fibrils in the second selection
strategy were used. The first selection consisted of four panning cycles, and was carried
out in presence of a competitor in the solution. For this purpose, a tenfold surplus of freshly
dissolved Aβ42 peptide (acting as the competitor) was added to the solution. Biotinylated
Aβ42 oligomers from preparation IV were used as the antigen, and attached to the solid
surface (streptavidin-coated paramagnetic beads). The washing steps enabled the removal of
all binders that cross-reacted with the competitor (Figure 3.2). The second selection strategy
also consisted of four panning cycles, but it was performed in absence of a competitor in the
solution. Biotinylated Aβ42 oligomers (preparation I), immobilised on streptavidin-coated
paramagnetic beads served as the antigen. Both selections were carried out in parallel. A
comparison of the two selection strategies is given in Table 3.1.
(a) (b)
Figure 3.2. Selection in a competitive environment using the phage display procedure. Phages
displaying specific antibody domain bind to the immobilised target. Unspecific phages and cross-
reacting with Aβ42 peptide, are eluted in consecutive 20 washing steps (a). Schematic of the phage
display selection (b).
3.1.3 Evaluation of the specificity of selected VHH domains
To test whether the applied procedures were successful, ten single phage clones per
selection strategy were isolated. Next, phage clones were amplified in E. coli cells, and
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tested for binding to Aβ42 oligomers with phage ELISA. The principle of phage ELISA
differs slightly from a conventional ELISA. Instead of using purified antibodies, phage ELISA
uses whole M13 phages carrying VHH domains. Colorimetric detection is facilitated by a
secondary anti-M13 antibody, which is conjugated with HRP. Biotinylated Aβ42 oligomers,
immobilised on the streptavidin-coated ELISA plates with 96 wells, were used as a target for
the phage ELISA. Control wells were filled with Hepes buffer.
The results of the phage ELISA are presented in Figure 3.3. I found that the signal
produced by the binding to Aβ42 oligomers was generally strong, and comparable between
all of the tested clones AND the negative control (M13 helper phages). Optical density
(OD) signal of the phage ELISA ranged between 0.6 and 1.2 for the binding of the isolated
clones with Aβ42 oligomers. M13 helper phages also produced a strong binding signal for
Aβ42 oligomers (OD=1). No significant ELISA signal was detected for the reaction between
isolated clones and the Hepes buffer; OD for these wells was below 0.2.
Such high panning efficiency, with all of the isolated single phage clones binding to the
target, is unlikely. Should the selection be successful, I expected to obtain a binding signal
only for a few selected binders. In addition, the helper phages should not have produced a
binding signal to Aβ42 oligomers, since they do not display VHH domains on their surface.
Additional tests were performed to verify whether the selection was successful. Forty single
Figure 3.3. Results of the phage ELISA from two selection strategies. Grey bars: signal generated
by binding of single phages to biotinylated Aβ42 oligomers. White bars: signal generated by binding
of single phages to Hepes buffer (control). The binding of M13 helper phages to Aβ42 oligomers (red
bar) and Hepes buffer (black bar) served as a negative control. 1a–1j: single phages isolated from the
first selection strategy; 2a–2j: single phages isolated from the second selection strategy. Error bars:
SD (n = 2–3).
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clones which had passed the fourth round of panning (including the twenty tested with
phage ELISA, and additional twenty clones picked at random) were amplified and sequenced.
Analysis of their DNA sequences revealed that all of the forty selected binders were unique.
In theory, selection of forty successful oligomer binders is possible, but it would result in
an enrichment of their DNA sequences. M13 helper phages, used as a negative control for
phage ELISA, also strongly reacted with Aβ42 oligomers. This fact suggests an unspecific
interaction.
Additional phage ELISA was performed to test whether the interaction between the
oligomers and M13 phages is concentration-dependent. Biotinylated Aβ42 oligomers were
used as the immobilised ligand, while M13 helper phages were used as the binding partner.
The aim of this experiment was to exclude unwanted cross-reactivity between M13 helper
phages and Aβ42 oligomers. In the case that the interaction between Aβ42 oligomers and
helper phages was dependent on oligomers’ concentration, I would establish the minimum
concentration at which the reaction with phages does not occur. This concentration of
oligomers would be then used for the next selection procedure.
Different concentrations of biotinylated Aβ42 oligomers (preparation I and preparation
IV), ranging from 2 to 0.02 µg/well, were used for the phage ELISA. Hepes buffer was used as
a negative control, as it does not react with M13 phages. Interaction between Aβ42 oligomers
and M13 phages was detected with the anti-M13 antibody conjugated with HRP.
Aβ42 oligomers at concentrations equal to, or exceeding 1 µg/well reacted strongly with
helper phages (OD > 0.7). No interaction could be detected at concentrations equal to,
or lower than 0.2 µg/well for preparation I, and at concentrations equal to, or lower than
0.1 µg/well for preparation IV. These results suggest that the interaction between oligomers
and M13 helper phages is concentration-dependent (Figure 3.4). The problem of unspecific
interaction between M13 phages and Aβ42 oligomers could thus be overcome by decreasing
the concentration of the antigen.
47
RESULTS
!"#$%&'()*%+*'+,(-,#%+)./$0
!
1
,#
*
-
")
2
'
+
3
#,
4
●
●
●
●
●
● ● ●● ● ● ● ● ● ●
5 678 6 978 975 976 9798 9795
979
975
97:
97;
97<
679
675
67:
(a)
● ●
●
●
●
● ● ●
!"#$%&'()*%+*'+,(-,#%+)./$0
!
1
,#
*
-
")
2
'
+
3
#,
4
● ● ● ● ● ●
●
5 678 6 978 975 976 9798 9795
979
975
97:
97;
97<
679
(b)
Figure 3.4. Binding of wild type
M13 helper phages to Aβ42
oligomers. Black dots: concentration-
dependent binding of M13 helper
phages to preparations I (a) and IV
(b) of Aβ42 oligomers. Grey dots:
interaction of M13 helper phages with
Hepes buffer. Error bars: standard
deviation (SD; n = 2–3).
3.1.4 Optimisation of the selection strategy
Since both selection strategies failed to generate binders specific for Aβ42 oligomers, I
performed an additional selection under modified conditions. Based on the previous ELISA
results, I used between 0.5 and 0.15 µg of preparation I, and between 0.2 and 0.05 µg of
preparation IV. The selections of binders specific for both preparations were carried out in
parallel. The comparison of the two selection procedures is given in Table 3.2. After three
panning cycles, I picked twenty clones from each selection. The clones were sequenced and
tested for binding to Aβ42 oligomers with phage ELISA.
The phage display selection directed against preparation I failed to isolate a specific
antibody domain. Even though DNA sequence was identical in eight of the twenty isolated
clones, phage ELISA revealed that none of the twenty clones specifically interacted with
Aβ42 oligomers (data not shown). A specific binder also did not emerge from the phage
display selection directed against preparation IV: the sequences of all of the twenty clones
were different. A strong phage ELISA signal (data not shown) between M13 helper phages
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Table 3.2. The differences in conditions of selection strategies against preparations I and IV of
Aβ42 oligomers.
Preparation Amount Competitor Phage DNA Outcome of
of target sequences* antibody selection
I 0.5–0.15 µg Aβ42 fibrils during 8 identical one VHH domain;
preselection (20 µg) no affinity to
Aβ42 oligomers
IV 0.2–0.05 µg Aβ42 peptide in the all different no VHH domain
solution (100 µg) selected
* out of twenty in total.
and Aβ42 oligomers indicate the unspecific interaction.
Since both selection strategies failed to determine an antibody fragment specific for Aβ42,
I proceeded to the characterisation of the existing Aβ binders.
3.2 Molecular characteristics and assessment of specificity of fibril-specific antibody
fragments
3.2.1 Large-scale expression and purification of B10 and B10AP
The B10 VHH domain, directed against Aβ40 fibrils, had previously been generated with
the phage display selection technique (Habicht et al. 2007). Recombinant availability of B10
facilitated the generation of the genetic fusion protein with AP; the product of the fusion was
termed B10AP (Figure 3.5).
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Figure 3.5. Dimerisation of the VHH domain.
Schematic illustration of whole camelid IgG,
VHH domain and the bivalent VHH-AP after
genetic fusion with alkaline phosphatase.
B10 and B10AP were periplasmically expressed in E. coli cells. Large-scale expression
was performed under strictly controlled conditions in 400 ml vessels, in a process called
high cell density fermentation (Figure 3.6a). The expression yielded 100 g of E. coli cells
(fresh weight). WB analyses were carried out to test the expression level of the recombinant
antibody domains after each fermentation. The resultant 16 kDa and 63 kDa bands on a PVDF
membrane indicated that both B10, and B10AP were successfully expressed (Figure 3.6b).
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Figure 3.6. Large-scale expression of B10 and B10AP. B10 fermentation in 400 ml vessels (a).
Expression of the B10 and B10AP was triggered by addition of 1 mM IPTG and visualised with WB
(b). 63 kDa bands correspond to B10AP (line 1 and 2). B10 is represented as a 16 kDa bands (line
3 and 4); lines 1 and 3 show expression level two hours after IPTG induction; lines 2 and 4 show the
expression four hours after addition of the IPTG. The fermentation was carried out in collaboration
with Uwe Knüpfer (HKI, Jena).
NiNTA and RPC chromatographic columns were used to purify B10; B10AP was purified
with NiNTA and QSepharose columns (see section 2.3.5 for the detailed conditions). The two-
step purification produced pure B10 domains; their purity was confirmed with SDS-PAGE
under denaturing conditions. The 16 kDa and 63 kDa bands on the Coomassie-stained gel
corresponded to the monovalent B10 and the bivalent B10AP, respectively (Figure 3.7).
3.2.2 Screening of the B10 epitope with a peptide phage library
Several biochemical (e.g. ELISA, spot blot) and biophysical (e.g. SPR) techniques have
been applied to determine the conformational specificity of B10 to Aβ40 fibrils (Habicht et al.
2007). However, the B10 epitope and the detailed binding mechanism remained unclear.
I aimed to acquire more precise information about the B10 epitope with the use of two
commercial peptide phage libraries. Both libraries consisted of 109 unique seven amino-
acid sequences displayed on the surface of the M13 phages. The first of those libraries
was a ‘cyclic’ library, where each peptide was constrained by a cysteine disulphide bridge,
and displayed in a loop form (Figure 3.8a); in the second, ‘linear’ library, each peptide was
displayed in a linear form (Figure 3.8b).
B10AP served as bait for the peptide ligand selection. Immobilisation of the antigen is
required for phage display. It was achieved in the following way: B10AP was N-terminally
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Figure 3.7. Purification of B10AP and B10. Chromatograms obtained after final purification steps of
B10AP (a)and B10 (c). The coomassie-stained gels after two-step purification of B10AP (b)and B10
(d). Lines on the gels: 1: lysate; 2: flow through after NiNTA; 3: eluate after NiNTA; 4: eluate after
IEC ∼63 kDa B10AP protein (b), and eluate after RPC ∼16 kDa B10 protein (d). MW: molecular
weight.
(a)
(b)
P1: FKLDGWY (9×)
P2: LRLEGWY (3×)
(c)
Figure 3.8. Selection with peptide libraries.
Schematic illustration of the cyclic peptide library:
seven amino acid peptide (slate circles) is constrained
by two cysteines at the end (black circles) and displayed
on M13 surface as a loop (a), and linear library: seven
amino acid peptide (slate circles) displayed in a linear
way on the M13 phage tip (b). Two peptide sequences
(P1 and P2) selected from the cyclic library after three
rounds of panning (c).
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biotinylated prior to the selection procedure (as described in section 2.4.1), and immobilised
on streptavidin-coated paramagnetic beads. Three rounds of panning were performed with
each of the two libraries. To test whether the selection was successful, the DNA of forty
individual M13 phage binders (twenty from each library) was isolated and sequenced.
The DNA sequences of all of the clones from the linear library were unique. In contrast,
panning with the cyclic library selected two predominant binding motifs, i.e., two sequences
appeared more than once among the twenty sequenced clones. These two DNA sequences
were translated into their respective amino acid sequences; they are referred to here as P1 and
P2 (Figure 3.8c). Among the twenty clones from the cyclic library, P1 occurred nine times,
while P2 appeared three times. P1 and P2 peptides were synthesised chemically, and checked
for binding to B10 with SPR.
To test whether selected peptides can inhibit the binding of B10 to amyloid fibrils,
competitive conditions were chosen for the SPR study. Prior to the injection of B10 onto
the fibril-coated SPR chip, a 400 nM sample of B10 was mixed with various concentrations
of P1; these concentrations ranged between 31.25 and 4000 nM. Subsequently, the interaction
of the mixture with Aβ40 fibrils was tested. The strength of the B10-fibril interaction was
independent of the concentration of P1; similar SPR signals were produced by a sample of B10
mixed with P1, and by an untreated sample of B10. Clear differences in the SPR signal were
observed for the variants with various B10 concentrations (Figure 3.9a), but the SPR signal
was not changed by the addition of P1 (Figure 3.9b). In the case of the P2 peptide, only one
concentration was tested; 4 µM were combined with a 400 nM sample of B10, and examined
for binding to Aβ40 fibrils. Similarly to P1, no effect was found on the B10-fibril interaction
(Figure 3.9c). SPR analysis did not confirm that the binding of the selected peptides to B10
was specific. This indicates that the seven amino-acid ligands were insufficient to inhibit the
binding of B10 to Aβ40 fibrils, and to define the structural epitope of B10.
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Figure 3.9. Effect of P1 and P2 peptides on
the binding of B10 to Aβ40 fibrils. SPR re-
sponse curves of the B10 binding to Aβ40 fibrils
(a). SPR responses from the interaction of the
B10-P1 mixture with fibrils (b). SPR responses
from the interaction of the B10-P2 mixture with
fibrils (c). SPR studies were performed in col-
laboration with Peter Hortschansky (HKI, Jena).
3.2.3 Characterisation of the B10 binding specificity
In order to test the binding properties of B10, several different amyloid or amyloid-like
fibrils (Table 3.3) were prepared, and characterised structurally. All of the tested fibrils possess
a generic amyloid backbone structure, as verified with ThT fluorescence, X-ray diffraction,
or ATR-FTIR spectroscopy. However, they vary with regard to length of the polypeptide
chains (full-size proteins and peptide fragments), general morphology (curvilinear, worm-
like fibrils, or straight fibrils), chirality of the polypeptide backbone (peptide consisting of
D-amino acids or L-amino acids), handedness of the fibril supertwist (left handed or right
handed), and presence of parallel or antiparallel β-sheet structure. Furthermore, some of the
analysed fibrils are associated with diseases (e.g., hSAA or transthyretin), while others are
not (e.g., glucagon or apomyoglobin fibrils). The fibrils are depicted in Figure 3.10, and their
characteristics are summarised in Table 3.3.
To assess the specificity of B10AP to previously analysed fibrils, a spot blot analysis was
performed. For the spot blot assay, amyloid and amyloid-like fibrils were immobilised on
a nitrocellulose membrane, and tested for binding to B10AP (Figure 3.11). The alkaline
phosphatase moiety of B10 facilitated a colorimetric detection of B10 binding to fibrils,
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Table 3.3. Characteristics of amyloid or amyloid-like fibrils
Polypeptide chain Characteristic No. of negatively Conditions
component features charged residues of preparation
Aβ40 Long, straight 7 out of 40 1 mg/ml; 50 mM sodium borate
pH 9.0 RT; 7 d
Ccβ Short, straight 6 out of 17 1 mg/ml; 200 mM sodium phosphate
pH 7.2; 37 ◦C; 7 d
Aβ(16–22) Long, straight 1 out of 7 0.5 mg/ml; H2O; pH 7.4
10 mM sodium azide; RT; 10 d
Insulin Long, straight 4 out of 51 1 mg/ml; H2O
pH 2.0; 60 ◦C; 2 d
Glucagon Long, straight 3 out of 29 1 mg/ml; 50 mM sodium phosphate
pH 3.0; 4 ◦C; 2 d
Apomyoglobin Short, curvilinear 21 out of 153 1 mg/ml; 50 mM sodium borate
pH 9.0; 65 ◦C; 7 d
G-Helix Long, straight 1 out of 18 1 mg/ml; 50 mM sodium borate
pH 9.0; 60 ◦C; 7 d
L-hSAA(1–12) Long, straight 2 out of 12 10 mg/ml; 10% acetic acid
pH 2.0; RT; 1 d
D-hSAA(1–12) Long, straight 2 out of 12 10 mg/ml; 10% acetic acid
pH 2.0; RT; 1 d
hSAA(2–21) Short, straight 3 out of 20 10 mg/ml; 50 mM sodium phosphate
pH 1.0; RT; 4 d
hSAA Short, curvilinear 16 out of 104 10 mg/ml; 50 mM sodium phosphate
pH 1.0; RT; 4 d
mSAA Short, curvilinear 16 out of 103 5 mg/ml; 50 mM sodium phosphate
pH 3.0; 37 ◦C; 2 d
Human calcitonin Short, straight 1 out of 32 1.5 mg/ml; 20 mM sodium acetate
pH 7.5; RT; 7 d
HET-s(218–289) Long, straight 9 out of 71 1.5 mg/ml; 40 mM boric acid; pH 3.0
pH 3 10mMcitric acid; 6mMNaCl; 37 ◦C; 7 d
HET-s(218–289) Long, straight 9 out of 71 1.5 mg/ml; 150 mM acetic acid
pH 7.5 pH 7.5 (adjusted with 3 M Tris)
RT; immediate formation of fibrils
PABN1-(+7)Ala Long, straight 28 out of 152 1 mg/ml; 5 mM potassium phosphate
pH 7.4; 150 mM NaCl
1% sodium azide; 37 ◦C; 30 d
Ure2p(10–39) Short, straight 2 out of 30 0.25 mg/ml; 10 mM sodium phosphate
pH 7.4; RT; immediate fibril formation
β2-microglobulin Long, straight 3 out of 22 0.25 mg/ml; 20% TFE; 10 mM HCl
(20–41) 1 mM NaCl; pH 7.5; 25 ◦C; 1 d
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eliminating the need to use a secondary antibody. Equal loading of the fibrillar proteins on
nitrocellulose membrane was confirmed with Ponceau S staining.
Figure 3.10. Negatively stained TEM images of in vitro amyloid or amyloid-like fibrils tested for
binding to B10AP. TEM images obtained in collaboration with Christian Haupt (MPRU, Halle)
Figure 3.11. Assessment
of the B10AP specificity
to amyloid fibrils. Grey
bars: B10AP staining;
white bars: Ponceau S
staining. B10AP and
Ponceau S staining of
Aβ40 fibrils was used as
reference for full stain-
ing. Spot blot assay was
performed in collabora-
tion with Christian Haupt
(MPRU, Halle).
Most of the analysed fibrils (i.e., insulin, Ure2p (10-39), G-helix, or hSAA) showed a
strong interaction with B10AP, and were thus categorised as B10-positive. Such a common
recognition mechanism cannot be easily explained on the morphological level, since B10
recognises long, straight fibrils (e.g., Aβ40 or glucagon fibrils), as well as short, curvilinear
fibrils (e.g., mSAA or hSAA fibrils). Interestingly, B10 equally binds fibrils derived from
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different polypeptide chains, as well as fibrils with opposite chirality – such as D-hSAA(1-12)
and L-hSAA(1-12). However, some of the tested fibrils did not show a significant interaction
with B10AP (they were categorised here as B10-negative), even though their morphological
or structural features are not distinctively different to B10-positive fibrils. B10-negative fibrils
also include fibrils derived from the same polypeptide chain, but from its different fragments
(e.g., Aβ(16–22) or hSAA(2–21)). Furthermore, B10 binding is neither stereospecific, nor
dependent solely on the presence of the parallel β-sheet structure. These observations indicate
that the presence of the amyloid-backbone structure of the fibrils does not suffice to explain
the B10-fibril interaction.
3.2.4 Relevance of positively charged CDRs of B10 for Aβ fibril recognition
Previous analysis of the B10 binding specificity revealed that B10 possesses a poly-
amyloid-specific binding. The 23-residues-long CDRs of B10 contain nine positively charged
amino acids, while negatively charged residues are absent (Figure 3.12). This suggests that
ionic interactions may be involved in how B10 recognises fibrils. To examine the effect of
the positively charged residues, 23 single-site B10 mutants were generated by replacing each
amino acid in the CDRs with alanine (performed in collaboration with C. Haupt, MPRU,
Halle). The binding of the B10 mutants to amyloid fibrils was tested with SPR: 1:100 N-
terminally biotinylated Aβ40 fibrils and 1:1 biotinylated Aβ40 disaggregated peptides were
immobilised on a streptavidin-coated SPR sensor chip. Various concentrations of the B10
mutants were applied, and the affinity for fibrils was measured. A steady state affinity model
was fitted to the raw SPR data.
DYKDEVQLVE SGGGLVQPGG SLRLSCTASG YTFSHRYHRW 
FRQAPGKERE IVAVISQSGM RTYYADSVKG RFTISRDNAK 
NTVYLQMNSL KPEDTAMYYC AAGTRKNVWT RQHPFDYWGQ
GTQVTVSSAS GADHHHHHH 
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Figure 3.12. Amino acid sequence of B10. Blue: positively charged CDR residues; black: uncharged
CDR residues; grey: framework residues.
We found that the aKD of the different mutants varied significantly, with the lowest value
observed for the T104A mutant (386 ± 46 nM), and the highest for the R39A mutant (2,950
± 742 nM). These values were compared with previously determined aKD for monovalent
B10 (475 ± 54 nM). In general, it became clear that the mutations of all positively charged
residues decreased the affinity of B10 to amyloid fibrils (Figure 3.13). No significant effect
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Figure 3.13. Evaluation of the B10 mutants affinity to Aβ40 fibrils. Apparent KD for every single
alanine B10mutant was measured with SPR.White bars: basic residues; grey bars: uncharged residues;
black bar: wild type B10 (control). Two mutants with the highest influence on the B10 affinity to
fibrils are circumscribed in red. aKD: apparent dissociation constant; wt: wild type. SPR studies were
performed in collaboration with Peter Hortschansky (HKI, Jena).
was observed for those mutants in which an uncharged residue was replaced with alanine.
The most pronounced effect was observed for two mutants: R39A (Figure 3.14a) and R61A
(Figure 3.14b). Subsequently, we generated a R39/61A double mutant, and tested its binding
to Aβ40 fibrils (Figure 3.14c). Its affinity for fibrils was so weak that determination of the aKD
value was not possible (Figure 3.14d). Analysis of the B10 crystal structure shows that R39
is situated within a β-strand, inside the B10 structure. Furthermore, R39 forms polar contacts
with several residues within the CDR3 and thus partially stabilises it. These observations may
explain the striking influence of R39Amutant on the B10 affinity to Aβ40 fibrils. Residue R61
is located on the surface of the B10 structure, and is the only basic residue within the CDR2
(Figure 3.15). The positively charged residues, present within the CDRs of B10, have a strong
influence on the affinity of B10 to fibrils; this influence indicates that ionic interactions are
involved in B10-fibril recognition.
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Figure 3.14. Interaction of the B10 mutants with Aβ40 fibrils. SPR response curves of the R39A
(a), R61A (b)and R39A/R61A (c)B10 mutants interaction with Aβ40 fibrils. Kinetic fits of the wild
type B10 and its mutants R39A and R61A, provided at the steady state binding. No fit is provided for
R39A/R61A mutant due to the very low response signal. Data were fitted with a steady state affinity
model (d).
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Figure 3.15. Crystal structure of B10. The positions of
CDR residues R39 and R61 are shown in the B10 crystal
structure. Red: CDR1; blue: CDR2; green: CDR3. In
collaboration with Isabel Morgado (MPRU, Halle)
3.2.5 Analysis of the structural recognition of two B10 variants with scrambled CDRs
3.2.5.1 Generation of the two B10 variants
Two additional B10 variants were constructed to further demonstrate the relevance of the
positively charged amino acids within the CDRs for fibril binding. The B10 mutants were
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generated from synthetic genes, which were obtained from a commercial source.
The sequential analysis of the CDRs of B10 showed the importance of positively charged
residues for the interaction with Aβ fibrils. This observation suggests the existence of an
acidic potential on the surface of Aβ fibrils. However, it has previously been demonstrated
that amyloid fibrils interacted with heparin, or other highly sulphated glycosoaminoglycanes.
This, in turn, suggested that the surface of the fibril has basic properties (Kisilevsky 2000).
Therefore, B10glu – the first variant – was designed so that all of the positively charged
residues in the CDRs were replaced with glutamic acid. B10glu was generated to test
the influence of the negatively charged residues in CDRs, in absence of positively charged
residues, on the interaction with Aβ fibrils. The second variant – B10scr – was constructed
to test the relevance of the positions of the particular amino acids. This variant contained the
same amino acids within the CDRs, but their order was randomly rearranged (Figure 3.16).
Figure 3.16. CDRs of B10 and two variants of B10. Blue: basic residues; red: acidic residues.
The obtained synthetic genes were cloned into an expression vector ptetpA6H for the
fusion with AP. Large scale expression of B10scr_AP and B10glu_AP was carried out by
means of periplasmic secretion in an E. coli strain RV308. Purification of the B10scr_AP
and B10glu_AP variants was performed according to the basic protocol for B10AP; some
modifications were applied wherever necessary (see section 2.3.5). The final results of the
purification of both B10 variants are shown in Figure 3.17.
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Figure 3.17. Results of the B10 variants
purification. B10 variants (63 kDa) on the
Coomassie-stained SDS-PAGE after ion ex-
change purification. Lane 1: B10glu_AP; lane
2: B10scr_AP.
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3.2.5.2 Analysis of the interaction of B10 variants with Aβ fibrils
Spot blot and ELISA assays were carried out to analyse the binding properties of the B10
variants. For the spot blot assay, Aβ40 fibrils were spotted on a nitrocellulose membrane.
Ponceau S staining was performed to confirm equal protein load on the membrane; Aβ40
fibrils were taken as the reference for maximum staining (Figure 3.18). Subsequently, the
membrane was incubated with B10scr_AP, B10glu_AP, and B10AP. B10AP staining of
Aβ40 fibrils was defined as the reference for maximum staining. The analysis showed that
staining intensity of Aβ40 fibrils with B10scr_AP is as strong as with B10AP. In contrast to
B10scr_AP, B10glu_AP variant showed significantly reduced staining intensity of fibrils –
only 20% of that obtained with B10AP.
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Figure 3.18. Spot blot assessment of the B10 variants interaction with Aβ40 fibrils. Staining of
Ponceau S or B10AP and its variants to Aβ40 fibrils as indicated (duplicates shown) (a). Quantified
Ponceau S and B10 variants staining intensities. White bars: staining of Aβ40 fibrils with Ponceau S.
Grey bars: staining level of B10AP, B10scr_AP and B10glu_AP to Aβ40 fibrils (b).
The removal of the basic residues prevented B10 binding to the fibrils. This result
confirmed the importance of the positively charged residues within CDRs for the B10-fibril
recognition. However, it came as some surprise that the different arrangement of the amino
acids within the CDRs of the B10scr_AP did not affect its affinity to fibrils. This demonstrates
that the B10scr_AP mutant, despite of a different conformational arrangement, is a functional
antibody which binds to amyloid fibrils.
To confirm the interaction between the B10scr_AP and Aβ40 fibrils, and the lack of
the interaction for B10glu_AP, an ELISA study was performed. Four different amounts
of biotinylated Aβ40 fibrils were immobilised on a streptavidin-coated ELISA plate, and
incubated with B10AP, B10scr_AP and B10glu_AP. The ELISA signal was developed by
colorimetric detection of the AP moieties (Figure 3.19). The most intense B10AP and
B10scr_AP signals were produced with the highest amounts of Aβ40 fibrils. The strength
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of the ELISA signal was slightly weaker at lower amounts of fibrils. Almost no interaction
between fibrils and B10glu_AP was detected, regardless of their concentration. Therefore, the
ELISA results fully confirmed the spot blot analysis.
Both analyses indicated that not the actual arrangement of the basic residues within the
CDRs, but their presence alone is key to the interaction with the fibrils. The presence of
several basic residues, and formation of a highly basic surface potential, are necessary for the
B10-fibril binding to occur.
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Figure 3.19. Examination of bind-
ing of the B10 variants to Aβ40 fib-
rils with ELISA. Binding of B10AP
(grey bars), B10scr_AP (white bars)
and B10glu_AP (black bars) to Aβ40
fibrils. Labels at the bottom indicate
the amounts of the fibrils per well.
3.2.6 Investigation of KW2 and KW3 VHH domains
3.2.6.1 Generation of functional KW2 and KW3 VHH domains
Apart from B10, two other Aβ40 fibril specific binders were generated in house from the
HKI library. They were termed KW2 and KW3 VHH domains. I compared the KW2 and
KW3 with B10 to further understand the mechanism of binding of VHHs with fibrils.
It was necessary for the further analysis to express the two antibody fragments at high
yields. To reach this goal, the TAG ‘amber’ nonsense codon was removed from the initial
KW2 and KW3 coding sequences (which were obtained by phage display), and replaced with
a codon for glutamine. Subsequently, KW2 and KW3 genes were cloned into expression
plasmids, and expressed in the E. coli RV308 strain as monovalent or bivalent (fused with AP)
molecules. KW2, KW3 and their AP derivatives were purified as described earlier for B10.
3.2.6.2 Measurements of the affinity of KW2 and KW3 to Aβ40 fibrils
The conformational sensitivity of KW2 and KW3 to Aβ40 fibrils was established with
spot blot and ELISA assays (K. Wielgmann, unpublished data). To ascertain the aKD value of
KW2 and KW3 for binding to Aβ40, SPR measurements were taken. In addition to KW2 and
KW3, KW1 and B10 domains were used as a controls for SPR study; B10 served as a positive
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control, while KW1 served as a negative control. The sensor chip used for the SPR analysis
was coupled with Aβ40 fibrils and disaggregated Aβ40 peptide.
The aKD values were calculated based on the SPR response signals (Figure 3.20). aKD
values calculated for the interaction between Aβ40 fibrils and monovalent VHHs were 190
±29 nM and 186±28 nM for KW2 and KW3, respectively. The AP-fusions produced smaller
aKD values due to the bivalent functionality. aKD values were 30 ±1.6 nM for KW2AP and
11 ±1.0 nM for KW3AP. These values corresponded well to the B10AP affinity for Aβ40
fibrils calculated earlier (Habicht et al. 2007). As expected, KW1 and KW1AP did not show
any interaction with Aβ40 fibrils. The studied VHH domains did not produce a significant
response in the flow cell with the immobilised disaggregated Aβ40 peptides. These data show
that KW2 and KW3 are comparable with B10 with regard to the affinity to fibrils .
(a) (b)
Figure 3.20. Affinity of VHH domains for Aβ40 fibrils. Different concentrations (ranging from 800
to 25 nM) of B10, KW1, KW2, KW3 (a)and their AP derivates - concentrations ranging from 100
to 3.125 nM (b)were applied on Aβ40 fibril-coated sensor chip and their binding at steady state was
measured. Steady state fits (coloured lines) were obtained from the SPR responses from each VHH
concentration. SPR measurements were performed in collaboration with Peter Hortschansky (HKI,
Jena).
3.2.6.3 Sequence analysis of KW2 and KW3 domains
Previous analyses of B10 revealed that positively charged amino acids in CDRs are
responsible for the binding to Aβ40 fibrils. To search for potential commonalities among
the fibril binders, I examined the CDRs of KW2 and KW3. I found striking similarities to
B10 in terms of the enrichment of the positively charged residues in the CDRs (Figure 3.21).
Seven of twenty residues in the CDRs of KW2 are positively charged; four of those are
arginines. In KW3, eight of twenty amino acids in CDRs are positively charged, with six
arginines, one lysine, and one histidine. Negatively charged amino acids are absent in both
KW2 and KW3, similarly to our previous observations of B10. In contrast to B10, however,
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the CDR3 regions of KW2 and KW3 contain only nine residues, while CDR3 of B10 is longer,
containing twelve residues. Moreover, the CDRs of the three examined VHHs differ in terms
of the positions of the positively charged residues, as well as their occurrence in the individual
CDRs (Figure 3.21). The CDR1 of B10 and KW2 contains four basic residues, whereas the
CDR1 of KW3 contains a single one. Furthermore, the CDR2 of KW2 and B10 contains
only one basic residue, while three basic residues occur in the CDR2 of KW3. Finally, the
CDR3 of KW2 contains two basic residues, which is two fewer than the CDR3 of both B10
and KW3. Interestingly, the two most prominent positions in B10 in terms of fibril binding –
R39 and R61 – are occupied by the same residues in KW2, but differ in case of KW3 by one
substitution: position 39 is occupied by tryptophan instead of arginine. Despite the differences
in the position of the basic residues, however, B10, KW2, and KW3 show an equally strong
affinity to Aβ40 fibrils. These results emphasize the role of the basic residues in fibril binding,
and indicate that the position of the basic residues within the CDR is of minor importance,
unless sufficient quantity of basic residues is present.
Figure 3.21. CDRs of fibril specific VHH domains. Antigen binding regions of B10, KW2 and KW3
are rich in positively charged (+) residues (marked in blue), whereas negatively charged (–) are absent.
3.3 Molecular characteristics and assessment of specificity of KW1, an oligomer-
specific antibody fragment
3.3.1 Analysis of the conformational sensitivity of KW1 antibody fragment
KW1 and KW1AP, antibodies directed against Aβ40 oligomers, were also generated in
house from the HKI library. To express KW1, it was cloned into the p41_6His expression
vector, resulting in a monovalent VHH expression – as a single antibody domain. To generate
KW1AP, KW1 was cloned into the ptetpA6H vector (for the bivalent expression). The cloning
process was followed by recombinant expression of both VHHs in the periplasmic space
of E. coli cells. KW1 and KW1AP were purified with two-step column chromatography,
similarly to the purification of B10 (section 3.2.1). KW1 and KW1AP bind to Aβ40
oligomers, but neither to Aβ fibrils, nor to disaggregated Aβ peptide, as established with
ELISA and spot bot assays (Morgado et al. 2012). The ability of KW1 to recognise a certain
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structural arrangement, but not merely a polypeptide chain, qualifies it as a conformationally
sensitive antibody.
To obtain the Aβ40 oligomers for the analyses of the conformational specificity of KW1,
I dissolved the Aβ40 peptide in 100% HFIP, followed by dilution with H2O (ratio 1:10),
and centrifugation (see section 2.5.1 for the detailed protocol). HFIP is known to prevent
aggregation of oligomers into amyloid fibrils; it also stabilises the transient oligomeric
species. Prior to the investigation of the conformational specificity of KW1 to oligomers,
I tested the stability of Aβ40 oligomers by incubation in a 10% HFIP solution at 4 ◦C for
4 weeks. Aliquots of Aβ40 oligomers were taken directly after preparation, and after the
incubation. The aliquots of oligomers were negatively stained with 2% uranyl acetate and
analysed with TEM. Obtained images confirmed the absence of fibrillar aggregates in the
oligomeric preparations in both samples – directly after the preparation, and after the four-
week-incubation period (Figure 3.22). The morphology of Aβ40 oligomers did not change
significantly. This demonstrates that HFIP acts as a sort of a conformational trap, capable of
stabilising the oligomers for several weeks.
(a) (b)
Figure 3.22. Negatively stained Aβ40 oligomers. TEM images of Aβ40 oligomers in 10% HFIP
directly after preparation (a), and after four weeks of incubation period at 4 ◦C (b). Scale bars: 100
nm.
I performed SPR measurements to further confirm the observation that KW1 binds to
Aβ40 oligomers. To immobilise the target – a prerequisite for the SPR measurements –
the biotinylated Aβ40 oligomers were attached to a streptavidin-coated SPR sensor chip
(Figure 3.23a). To account for the transient nature of the oligomeric species, the oligomers
were stabilised on the sensor chip by means of EDC-NHS cross-linking. In addition to the
Aβ40 oligomers, the sensor chip was coupled with Aβ40 fibrils and disaggregated Aβ40
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peptides on the other flow cell; it served as a control. Six different concentrations of KW1AP
(200, 100, 50, 25, 12.5, and 6.25 nM) were applied to the sensor chip. Based on the SPR
response signals, the aKD was determined (Figure 3.23b). It equalled 43.5 ±4.9 nM for
KW1AP binding to Aβ40 oligomers. Molar stoichiometry of binding, measured with SPR,
equalled 1:13 (KW1:Aβ).
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Figure 3.23. KW1AP affinity
to Aβ40 oligomers. Biotinylated
Aβ40 fibrils, oligomers, and disaggre-
gated peptide were immobilised on a
streptavidin-coated SPR sensor chip.
Fourth flow cell served as a reference.
Presence of appropriate amyloid struc-
tures was confirmed with TEM (a).
SPR response curves of the KW1AP
binding to Aβ40 oligomers (pale blue
lines). Colour indicates increasing
concentration of KW1AP (from 6.25
to 200 nM). Two measurements were
performed for each concentration. Red
lines represent global steady state fit
(b). Apparent dissociation constant
was measured based on the steady state
affinity model. SPR measurements
were performed in collaboration with
Peter Hortschansky (HKI, Jena).
3.3.2 The effect of KW1AP on disaggregation of Aβ40 fibrils
KW1AP binds to oligomers, which are known to be precursors of amyloid fibrils. It
has been demonstrated for other antibodies that their binding may disaggregate amyloid
conformers (Solomon et al. 1997). To test whether KW1AP can dissociate the preformed
Aβ40 fibrils, I carried out the following procedure: KW1AP was incubated with Aβ40 fibrils
(molar ratio 1:10) in 50 mM Hepes buffer (pH 7.4) at 37 ◦C. As a control, Aβ40 fibrils were
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kept under identical incubation conditions, except for the presence of KW1AP. After one
week, the samples were centrifuged and analysed with SDS-PAGE and TEM (Figure 3.24).
SDS-PAGE revealed that insoluble aggregates (pellet fraction, 4 kDa band) were present in
both samples: incubated in presence of KW1AP, or in its absence. Furthermore, mature
fibrils were found in both samples before centrifugation, as well as in the pellet fraction after
centrifugation (as established with TEM). Soluble forms of Aβ were observed neither on
the SDS-PAGE (in the supernatant), nor on the TEM images. The obtained results indicate
that KW1AP does not disintegrate preformed fibrils. As indicated by the 63 kDa band on
the SDS gel, KW1AP was primarily observed in the total sample before centrifugation, and
in the supernatant fraction. Presence of the 63 kDa band (KW1AP) in the pellet fraction
might be caused by the partial precipitation of the KW1AP, which may have resulted from
the incubation at 37 ◦C for one week, rather than from its interaction with fibrils. These data
indicate that KW1AP does not destabilise preformed Aβ40 fibrils.
A
     BC        S          P      BC        S          P
AF AF + KW1AP
63 kDa
 4 kDa
–
–
Figure 3.24. Evaluation of the potential of KW1AP to disaggregate Aβ. Aβ (4 kDa bands) and
KW1AP (63 kDa bands) on the Coomassie-stained gel after one-week incubation of Aβ fibrils (AF)
in presence or absence of KW1AP. Samples from the fraction before centrifugation (BC), from the
supernatant (S), and from the pellet (P) are presented on the gel (top panel). Negatively stained TEM
images show the presence of AF after incubation with KW1AP from the BC (bottom left) and P (bottom
right) samples. Scale bar: 200 nm.
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3.3.3 Investigation of the KW1AP oligomeric epitope formation
I carried out a 24 h kinetic assay to investigate KW1AP epitope formation during the β-
amyloid aggregation. Initially, I verified the dynamics of Aβ40 fibril formation with ThT. It
is known that the binding of ThT to Aβ40 aggregates leads to a significant increase in the
ThT fluorescence (Hortschansky et al. 2005). For the purpose of this analysis, 0.5 mg/ml of
Aβ40 peptide was incubated in 50 mM Hepes buffer (pH 7.4) at 37 ◦C for 24 h. An aliquot of
the incubated Aβ sample was withdrawn every hour throughout the whole time course of the
experiment. The aliquot was taken for the ThT fluorescence measurement, preparation of the
TEM grids, and for the verification of the KW1AP binding with spot blot. ThT fluorescence
measurements revealed a characteristic Aβ aggregation kinetic curve, split into two phases
(Hortschansky et al. 2005): nucleation-dependent lag (4.5 h) and growth phase (4.5–9 h) were
well resolved, and the plateau was reached after 9–10 h (Figure 3.25). Analysis of the Aβ
aggregates with TEM confirmed the ThT observation. First Aβ aggregates appeared on TEM
images after 4 h of incubation, which corresponds to the increase of ThT fluorescence. Mature
fibrils appeared after 9 h, and were present in every TEM sample until the end of incubation
period (Figure 3.26). The appearance of the fibrils on the TEM images corresponded with the
plateau of the elevated ThT signal.
Figure 3.25. Measurements of
ThT fluorescence. Aggrega-
tion of the Aβ40 peptide was
monitored with ThT fluorescence
(open circles). ThT fluores-
cence signal, recorded from ma-
ture Aβ40 fibrils prepared one
week earlier was used as a pos-
itive control (solid circles). HF:
mature Aβ fibrils in Hepes buffer
(pH 7.4).
KW1AP moiety was used for the spot blot assessment of KW1 binding to aggregating
Aβ, to eliminate the need to use a secondary antibody. In the spot blot assay, increasing
staining signal from KW1AP was observed after 6 h and onwards. It peaked at 8 h (85%), and
fluctuated until the end of the experiment at 24 h; the signal of Ponceau S staining was stable
throughout the whole incubation period, thus confirming the equal load of Aβ proteins on the
spot blot membrane (Figure 3.27).
These data indicate that the epitope which is recognised by KW1AP occurs during the Aβ
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Figure 3.26. Aβ40 aggregates during the 24h incubation assay. TEM images taken at various stages
of Aβ40 peptide incubation in 50 mM Hepes buffer (pH 7.4). Scale bars: 200 nm.
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Figure 3.27. KW1AP staining of aggregating Aβ. Black dots: Aβ staining with KW1AP; grey dots:
Aβ staining with Ponceau S. Staining of 10% HFIP oligomers with Ponceau S and KW1AP served as
a full staining reference (separated grey and black dot, respectively). Error bars: SD (n = 2–3).
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aggregation pathway (KW1AP signal between 40 and 90%, from 6 to 24 h), and is formed
before mature fibrils are present. In regard to the metastable character of oligomers and
their heterogeneous structure, the fluctuating pattern of the KW1AP signal may suggest their
transient presence.
The fact that definite binding (∼100%) signal from KW1AP was not reached may indicate
that the epitope of KW1AP did not manifest itself fully. The lack of oligomeric structures on
TEM images may not necessarily assert that oligomers are absent during the process of Aβ
aggregation; instead, they might have not been captured due to the one-hour-long sampling
intervals.
3.3.4 Structural analysis of various Aβ-derived oligomeric aggregates
To test specificity range of KW1AP, I performed structural studies of chosen oligomeric
species. These oligomers were prepared according to seven different protocols. The
oligomeric species were derived from Aβ40 and Aβ42 peptides, but different conditions of
preparation were applied (Table 3.4; see also section 2.6.2). Subsequently, I characterised
them morphologically with TEM, and structurally with ATR-FTIR. Table 3.4 also contains
a compilation of characteristic features of studied oligomeric species derived from Aβ40
(preparation. I, II and III) and Aβ42 (preparation I, II, III and IV).
The TEM analysis revealed that, except for preparation II of Aβ42 which generated
curvilinear morphologies, all Aβ oligomer preparations produced spherical conformers (Fig-
ure 3.28). Preparation I and II of Aβ40 as well as preparation II of Aβ42 yielded relatively
homogeneous oligomer populations. The remaining preparations provided a mixture of
morphologically diverse species.
Figure 3.28. Structure of Aβ oligomers. TEM images of various oligomeric structures: preparation
I, II and III of Aβ40 oligomers (top row) and preparation I, II, III and IV of Aβ42 oligomers (bottom
row). Scale bars: 200 nm.
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Table 3.4. Characteristics of selected oligomeric Aβ aggregates used in my research
Oligomers Preparation Structural features Interaction Preparation
with KW1AP conditions after
Aβ40 I 7–50 nm; spherical appearance; strong Habicht et al. (2007)
anti-parallel β-sheet
(Habicht et al. 2007)
II 7–10 nm; spherical appearance; strong Kayed et al. (2009)
parallel β-sheet
III 5–20 nm; spherical appearance; none Sarroukh et al. (2010)
anti-parallel β-sheet
(Sarroukh et al. 2010)
Aβ42 I 5–15 nm; spherical appearance; weak Kayed et al. (2003)
anti-parallel β-sheet
II 8–25 nm; curvilinear appearance; very weak Kayed et al. (2009)
anti-parallel β-sheet
III 7–25 nm; globular appearance; none Klein (2002)
anti-parallel β-sheet
(Cerf et al. 2009)
IV 7–20 nm; globular appearence; none Barghorn et al. (2005)
anti-parallel β-sheet
(Eckert et al. 2008)
Details of oligomer preparations are given in section 2.6.2
To gain insight into the secondary structure of oligomers analysed previously with TEM,
I performed structural study using ATR-FTIR. The ATR-FTIR is often use to distinguish
between a parallel and an antiparallel β-sheet structure based on the analysis of the amide
I region (1600-1700 cm–1; (Miyazawa and Blout 1961)). Presence of two components within
the amide I region, a major (with a reflectance maximum at ∼1630 cm–1), and a minor (with
a reflectance maximum at ∼1695 cm–1), indicates an antiparallel β-sheet structure; presence
of only the major component indicates a parallel β-sheet structure.
I recorded the FTIR spectra of Aβ40 oligomers (preparation I and II), and Aβ42 oligomers
(preparation I and II). The oligomers were prepared according to the procedure described in
section 2.8. The maxima of the amide I region of all examined oligomers were in the range
of 1630 cm–1, marking a significant content of β-sheet structure (Figure 3.29). Additionally,
a minor component was observed in the spectra of preparation I of Aβ40 oligomers, and
preparations I and II of Aβ42 oligomers, thus signifying an antiparallel β-sheet structure in
those species. The minor component was absent in case of preparation II of Aβ40 oligomers,
indicating a parallel β-sheet structure. As far as the remaining Aβ aggregates are concerned,
earlier FTIR studies revealed that preparation III of Aβ40 oligomers and preparation III and
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Figure 3.29. ATR-FTIR spectra from the amide I region of Aβ oligomers. Spectra were recorded
in H2O for four different preparations of oligomers: preparation I of Aβ40 oligomers (a), preparation
II of Aβ40 oligomers (b), preparation I of Aβ42 oligomers (c), preparation II of Aβ42 oligomers (d).
* indicates the peak at ∼1695 cm–1. Insets show TEM images of respective oligomeric preparations.
Scale bar: 200 nm.
IV of Aβ42 oligomers possess an antiparallel β-sheet structure (Sarroukh et al. 2010, Cerf
et al. 2009, Eckert et al. 2008).
3.3.5 Specificity assessment of KW1AP
To assess the specificity range of KW1AP antibody to the oligomeric species, I carried out
a spot blot analysis. For this purpose, seven previously structurally characterised Aβ-derived
oligomeric preparations (preparations I-III of Aβ40 and preparations I-IV of Aβ42) and six
non-Aβ-derived oligomers (SAA(2-21), full length SAA, glucagon, lysozyme, Sup35(7-13),
and apomyoglobin) were immobilised on nitrocellulose membrane and tested for binding to
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KW1AP. Staining with Ponceau S was performed to confirm equal protein load. The staining
of preparation I of Aβ40 oligomers with KW1AP and Ponceau S was used as full staining
reference.
Spot blot showed only a weak or no interaction of KW1AP with most examined species
(Figure 3.30a). The only significant interaction of KW1AP was observed with preparation II
of Aβ40 oligomers. Preparation III of Aβ40 did not show significant staining with KW1AP.
KW1AP also did not recognise Aβ42-derived oligomers, except from preparation I, which
showed some interaction with KW1AP (Figure 3.30a). Finally, there was no significant
interaction between KW1AP and non-Aβ-derived oligomers (Figure 3.30b).
These data let me conclude that KW1AP binds only to a certain type of oligomers, and
that this binding is independent from the oligomer’s polypeptide origin.
(a)
(b)
Figure 3.30. Binding of KW1AP to var-
ious oligomers. Several preparations of
Aβ (a)and non-Aβ (b)derived oligomeric
species were tested for binding to KW1AP
(grey bars). Equal load of the oligomeric
species on the membrane was confirmed
with Ponceau S staining (white bars). Error
bars: SD (n = 2–3). The specificity assess-
ment of the KW1AP was carried out in col-
laboration with Stefanie Brandt (MPRU,
Halle).
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Chapter 4
Discussion
In this dissertation, I analysed the structural diversity of Aβ by means of antibody recognition.
To improve our understanding of the delicate nature of Aβ aggregates, I employed a whole
spectrum of biophysical and biochemical methods. First, I described the selection process
of the antibody fragments directed against Aβ42 oligomers. However a specific binder
did not emerge during the selection process; therefore I proceeded with a characterisation
of previously generated antibody fragments specific to Aβ fibrils (B10, KW2 and KW3)
and Aβ40 oligomers (KW1). This characterisation yielded valuable information about the
mode of action of the studied antibody fragments, and provided insight into the structure and
biochemistry of different Aβ assemblies.
4.1 Selections of the VHH domain against Aβ42 oligomeric species
In an attempt to select a VHH binder specific to Aβ42 oligomers, I applied a camelid
phage library from the HKI. I prepared the targeted Aβ42 oligomeric species according to a
range of diverse protocols. I also implemented different selection conditions. Nonetheless, a
specific binder did not emerge during the selection process. In this chapter, I will discuss the
possible causes of this failure, which include the technical (phage display) and methodological
limitations (conditions of selection, transient nature of oligomers, and their tendency to
aggregate).
The first phage display selection against Aβ42 oligomers, though performed in the
presence of two competitors, was unsuccessful. All of the selected binders produced a
high signal to Aβ42 oligomer preparations (Figure 3.3), which might point to the successful
selection of an anti-Aβ42 oligomers antibody. However, the strong interaction between the
M13 helper phages (used as a negative control) and the oligomers, as well as the differences
in DNA sequences of the binders, clearly indicated that their interactions with oligomers
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were unspecific. Repeated selection under more stringent conditions, with much lower
concentrations of the antigen (Figure 3.4), also did not produce the expected output. The
high signal produced by selected binders to Aβ42 oligomers might be partially explained by
the unspecific binding of coat proteins of the M13 phage. Those proteins are abundantly
exposed on the phage surface and may bind with the antigen (Arap 2005). This applies
in particular to phage coat protein VIII (pVIII), which is represented on the surface of the
M13 phage by 2700 copies (Haigh and Webster 1998). pVIII consists of free segments
whose middle part is strongly hydrophobic (Marvin 1998, Haigh and Webster 1998). This
type of interaction may be responsible for the unspecific binding to Aβ42 oligomers, which
expose hydrophobic patches on their surface (Chen and Glabe 2006). Such interpretation is
further supported by the fact that Aβ42 oligomers show an affinity to phospholipid membranes
(Williams and Serpell 2011); therefore, the mechanism of M13 phage-oligomer interaction
may be analogous.
The relatively low diversity of the HKI camelid phage library is another potential cause
of the unsuccessful selection. The library consists of 6 × 108 functional clones (Habicht
2002). The size of the phage-based library is limited by the transformation efficiency of E. coli
cells. Much higher diversity can be reached in a ribosome-based library, which is only limited
by the number of ribosomes used for the reaction, and independent from the transformation
efficiency (Hanes and Plückthun 1997). Furthermore, the applied phage display procedures
did not include somatic hypermutation. Somatic hypermutation is a powerful mechanism,
which occurs naturally during in vivomaturation of antibodies (Wagner and Neuberger 1996).
This mechanism greatly increases the antibody repertoire, therefore has been replicated in the
ribosome display (He and Khan 2005). The ribosome display technique enables the insertion
of random mutations into the DNA sequence of antibodies during the PCR steps alternating
with the panning rounds (Hanes and Plückthun 1997). Perhaps another, alternative display
technique (e.g. ribosome display) could be used instead of phage display in further selections
of specific binders against Aβ42 oligomers.
Due to their transient nature, Aβ42 oligomers are a very challenging target. This could
be the ultimate cause for the failed selection of a specific binder. In comparison to Aβ40
species, Aβ42 oligomers have an increased tendency to aggregate. The C-terminal end of
Aβ42 peptide is very hydrophobic, and the peptides are more likely to interact with each other
through hydrophobic interactions. Therefore, the hydrophobicity of the peptide contributes
to the metastable character of Aβ42 oligomers. This feature may cause changes in the
exhibited structure of Aβ42 oligomers during phage display selection; it may also result in
the presentation of diverse epitopes to the VHH antibodies. Presentation of different epitopes
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during selection rounds possibly hindered the selection of a specific VHH antibody fragment.
Several antibodies against Aβ42 oligomers, generated during the process of animal immu-
nisation, have recently been described (Gong et al. 2003), but they recognise both oligomers
and fibrils (Lacor et al. 2004, Lambert et al. 2007). Furthermore, most of those antibodies
constitute polyclonal sera (e.g., A11), which uniformly bind to many Aβ and non-Aβ derived
prefibrillar aggregates (Kayed et al. 2003). This is not surprising: in a heterogeneous
population of oligomers, there exists a relatively high probability for polyclonal sera to bind
to different epitopes. In contrast, VHH domains are monoclonal. They can bind to only one
epitope; selecting a specific binder from among them is thus more challenging.
Despite the failed selection attempt, I argue that in vitro selection of binders against chosen
Aβ42 oligomeric species is a potentially successful approach. Some specific requirements
should be met: reaction conditions should be chosen carefully; the optimisation of panning
conditions should not be limited to the concentration of the antigen, but should also include
the type of the competitor and furthermore, cross-reactivity should be minimised. To account
for the tendency of oligomers to aggregate, as well as their sensitivity to solution conditions,
factors like salt concentration, the choice of buffers, and the system of elution should also be
revised.
4.2 Common binding mechanism of fibril-specific VHH domains
The aim of this dissertation was to clarify the molecular mechanisms of the interaction
between B10, KW2, and KW3 antibody fragments and amyloid fibrils. Elucidation of these
mechanisms would enable better understanding of the structure of fibrillar Aβ aggregates.
In this section, I will address these issues with particular emphasis on molecular recognition
pattern of the B10 antibody domain.
4.2.1 Linear ligands are insufficient to define the B10 epitope
Although the specificity of B10 for fibrillar Aβ40 aggregates was well determined
(Habicht et al. 2007), the B10 epitope remained to be established. My attempts to char-
acterise the B10 epitope with seven amino acid peptides derived from phage libraries were
unsuccessful (see section 3.1.2). In spite of the fact that two peptides were enriched after
three rounds of panning, none of them acted as a Aβ40 fibril competitor – as verified with
the SPR study (Figure 3.9). These results imply that the seven-residue peptide is incapable
of defining the conformational nature of B10 epitope. Similar endeavours to determine
epitopes of conformation-sensitive NU1, NU2 and NU4 anti-Aβ antibodies are described in
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the literature (Lambert et al. 2007). It was shown that short, Aβ-derived peptide fragments
did not suppress the binding of NU antibodies to Aβ conformers. However, pre-incubation of
NU antibodies with longer, 28 amino acid peptide fragments strongly inhibited the binding to
Aβ conformers (Lambert et al. 2007). My results indicate that seven amino acid peptides in
linear or cyclic form (Figure 3.8) are insufficient to determine the B10 epitope; this provides
indirect evidence for the higher complexity of the conformational epitope of B10.
4.2.2 Molecular basis of the conformation-specific binding of B10 to amyloid fibrils
A deeper understanding of the conformational specificity of B10 to amyloid fibrils was
provided by the investigation of the B10 complementary binding regions. SPR analysis of
24 B10 alanine single mutants revealed that B10 recognition of Aβ40 fibrils is mediated by
electrostatic interactions (Figure 3.13). Replacement of positively charged groups by alanine
in B10 significantly diminished the affinity of B10 to fibrils (Figure 3.13). Furthermore, the
double B10 mutant (R39/61A) did not interact with Aβ40 fibrils; therefore, I conclude that
cationic residues in CDRs of B10 are involved in fibril recognition. This conclusion was
further reinforced by the finding of Haupt et al. (2011b), who tested the effect of chemical
modifications of charged groups on Aβ40 fibrils (Figure 4.1a). Aβ40 fibrils with carboxyl
groups modified by glycinamide did not show any interaction with B10AP (Figure 4.1b;
Haupt et al. 2011b). Due to the fact that Aβ40 fibrils containing -NH2 groups masked by
NHS-biotin were still recognised by B10AP, it was concluded that fibril -COOH groups
constitute structural components responsible for binding to B10. In addition, the lack of
interaction between B10AP and carboxyl-modified fibrils was further demonstrated for G-
helix and insulin fibrils (Figure 4.1b; Haupt et al. 2011b). Accumulated data emphasise the
importance of negatively charged groups on fibrils for B10 antibody binding. This fact is
consistent with previous reports asserting that the binding of serum amyloid P component
(Thompson et al. 2002) and the apolipoprotein E (Gunzburg et al. 2007) depends on the
negatively charged groups on fibrils; albeit this type of interaction with fibrils is not common,
especially in the context of antibody recognition. The basic surface properties of amyloid
fibrils are well documented, since they were shown to react with anionic polymers like
heparin or glycosoaminoglycanes (Kisilevsky 2000). The B10 recognition mechanism also
significantly differs from Aβ-sequence-specific antibodies. Their interactions with fibrils are
based on the recognition of the combined cationic and anionic surfaces on fibrils (Gardberg
et al. 2007, Basi et al. 2010).
The crystal structure of B10 was determined at 1.8 Å resolution. It revealed a unique
property of B10, namely a substantially flat complementary binding region (Haupt et al.
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(a)
(b)
Figure 4.1. Modifications of fibrils influence the mechanism of recognition with B10. Amyloid fib-
rils were chemically modified with either NHS-biotin (to mask the amino groups), or with glycinamide
(to cover carboxyl groups on their surface) (a). Negatively stained TEM micrographs of Aβ40, insulin
and G-helix fibrils. B10AP (black bars) and Ponceau S (white bars) staining intensities of modified
fibrils. Unmodified fibrils were used as a reference for full staining (b). Images after Haupt et al.
(2011b).
2011b). The structure of the B10 CDRs is distinct from previously published sequence
specific antibodies directed against β-amyloid. Sequence-specific antibodies contain deep
binding pockets, formed by grooves of CDR1, CDR2 and CDR3. They encompass the N-
terminal part of the β-amyloid sequence (Gardberg et al. 2007, Basi et al. 2010). In the case
of B10, its flat recognition site perfectly matches the structurally even surface of amyloid
fibrils (Figure 4.2; Haupt et al. 2011b). The complementarity of the B10 surface arises from
the very regular surface pattern of amyloid fibrils. This pattern comprises ∼4.7 Å main chain
repeats between β-strands (Marshall and Serpell 2009), and 5–12 Å side chain separation
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along the fibril axis (Fändrich 2007). The CDRs of B10 cover the region of approximately
sevenβ-strands from the common core structure of amyloid fibrils (Haupt et al. 2011b). This
is in accordance with the 1:10 molecular stoichiometry of B10 binding to fibrillar Aβ40,
determined earlier using SPR (Habicht et al. 2007).
The accumulated data show that the B10 binding mechanism is unique. Mechanism of
fibril recognition by B10 involves both, electrostatic interactions and binding of the regular
surface pattern of Aβ40 fibrils.
Figure 4.2. Surface complementarity of B10 and amyloid fibrils. The flat binding surface of B10
complements the regular, structurally even surface of Aβ40 fibrils. Images after Haupt et al. (2011b).
4.2.3 B10 recognises a regular surface pattern of amyloid fibrils
The B10 antibody domain has previously been shown to recognise both the fibril and the
protofibril state of Aβ40; however, an interaction with oligomers or disaggregated peptides
was not observed (Habicht et al. 2007). Detailed assessment of the binding specificity of
B10 revealed that B10 recognises a whole spectrum of amyloid or amyloid-like fibrils. The
analysed fibrils differed significantly with regard to chirality of the backbone, handedness of
the fibril supertwist, presence of parallel or antiparallel β-sheet structure, length and origin
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of the amino acid sequence, or morphological appearance. Nevertheless, they all displayed
amyloid characteristics. Except for a small group of fibrils, which did not reproducibly react
with B10, the majority of the examined fibrils did. However, none of the aforementioned
fibrils’ characteristics can explain the interaction of the fibrils with B10AP. The non-reactive,
‘B10-negative’ fibrils display no obvious morphological or structural features which could
clearly prevent from binding of B10. Furthermore, some fibrils (i.e., Aβ(16–22) or hSAA(2–
21)) were derived from peptides fragments, which full polypeptide sequence formed ‘B10-
positive’ fibrils.
In vivo examination of amyloid tissue sections provided further evidence for the selective
B10 recognition of amyloid fibrils. It revealed that B10 binding is correlated only with
certain pathological amyloid conditions, i.e., Alzheimer’s disease and human cardiac ATTR
amyloidosis (Haupt et al. 2011a). However, B10 was not able to distinguish between fibril
morphologies from the same protein (Haupt et al. 2011a). All in vitro fibrils examined
with B10 contained negatively charged amino acids. The lack of B10 interaction with fibrils
containing acidic residues demonstrates that the presence of negatively charged groups on the
fibrils alone cannot explain the B10-fibril interaction. Detailed examination of the PABPN1–
(+7)Ala fibrils, which did not react with B10AP, provided a partial understanding of the B10
binding mechanism. The cross-β structure of PABPN1–(+7)Ala is formed by poly-alanine
extensions, and thus contains few charged residues in the core (Sackewitz et al. 2008); hence,
charged residues are not exposed on the surface of the cross-β structure. B10 was also
demonstrated to bind to anionic polymers, which are devoid of a protein-specific polypeptide
backbone, like DNA or heparin (Haupt et al. 2011a). However, no significant interaction was
observed between B10 and β-sheet-rich globular proteins, or intrinsically disordered peptides
(Haupt et al. 2011a). The fact that B10 does not react with β-sheet-rich proteins (i.e., Pel-15
pectate lyase or p22 tailspike protein) imposes structural constraints on the B10 recognition
mechanism. Furthermore, the globular proteins are rich in surface-exposed acidic residues;
nevertheless, binding with B10 does not occur. The arrangement of amino acids in globular
proteins, as shown for the transthyretin or P-15 pectate lyase (Figure 4.3a; Haupt et al. 2011a),
causes irregular surface texture with mixed positively- and negatively-charged groups. In
contrast, ‘B10-positive’ Aβ42 fibrils or HET-s(218–289) fibrils (Wasmer et al. 2008) display
a regular pattern of charges on their surface (Figure 4.3b; Haupt et al. 2011a). In light of this
evidence, I conclude that exhibition of negative charges and their arrangement in a regular
pattern on the fibril surface are plausible causes of the B10 recognition.
Finally, the B10-fibril interaction mechanism strongly resembles that of a class of pattern
recognition receptors typical for innate immunity (i.e., RAGE: receptors for advanced glyca-
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(a) Lysozyme (b) Transthyretin (c) Pel-15
(d) HET-s(218–289) (e) Aβ(1–42)
Figure 4.3. Comparison of
electrostatic surface potential of
globular and fibrillar proteins.
Globular proteins: lysozyme (a),
transthyretin (b), and Pel-15 (c),
are rich in unequally distributed,
negatively charged residues. In
contrast, negatively charged residues
on the surface of HETs(218–289) (d)
and Aβ42 (e) fibrils are distributed
regularly. Colour indicates the surface
charge potential (red: negative; blue:
positive; white: neutral). Images after
Haupt et al. (2011b).
tion end products). This similarity arises from the fact that the RAGE multiligand specificity
is characterised with strongly basic surface electrostatic potential (Haupt et al. 2011a). This
electrostatic potential imposes a mechanism of recognition via positively charged residues
(Xie et al. 2008). Additionally, a positively charged electrostatic surface of the RAGE-VC1
fragment (containing the ligand binding site; Dattilo et al. 2007), has many similarities with
the B10 binding site (Figure 4.4). The binding region of the RAGE-VC1 fragment does not
display apparent irregularities. Such irregularities are also not observed in the CDRs of B10
(Haupt et al. 2011a). This suggests that the binding region is flexible, making it prone to
rearrangement upon binding to a fibril. The RAGE-VC1 fragment was also proved to bind
to mature Aβ40 fibrils, but not to disaggregated peptides (Haupt et al. 2011a) – analogous to
B10 (Habicht et al. 2007). Furthermore, RAGE-VC1 recognises most of the ‘B10-positive’
fibrils, while the interaction with ‘B10-negative’ fibrils was not observed, with the exception
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of Aβ(16-22) fibrils (Haupt et al. 2011a). Remarkably, similar recognition mechanisms of
RAGE-VC1 fragment and the B10 domain emerged from radically different pathways; the
first evolved naturally, while the second was engineered biotechnologically with the use of
genetic methods (Haupt et al. 2011a).
(a) RAGE-VC1
(b) B10
Figure 4.4. Comparison of the electro-
static surface potential of RAGE-VC1 (a)
and B10 (b) . Colour indicates the surface
charge potential (red: negative; blue: pos-
itive; white: neutral). Images after Haupt
et al. (2011b).
4.2.4 Random rearrangement of B10 CDRs does not affect the interaction with fibrils
The analysis of binding properties of the two B10 variants: B10scr and B10glu, indicates
that random rearrangement of the residues in the CDRs does not influence the B10 interaction
with fibrils. The crystal structure of B10 does not display a regular pattern in the binding site,
but suggests considerable plasticity of this region. The flexibility of the binding site makes it
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prone to rearrangement upon binding to an antigen (Haupt et al. 2011b). This feature of B10
may, at least partially, explain the strong affinity of the B10scr variant to Aβ40 fibrils; B10scr
contains the same residues in CDRs as B10, but those residues are randomly rearranged. In
contrast, the B10glu variant, in which positively charged residues were replaced with glutamic
acid, did not interact with Aβ40 fibrils. This fact supports the previous finding that cationic
groups in the CDRs of B10 are essential for fibril recognition (Haupt et al. 2011b).
The observation that B10scr is capable of complexing Aβ40 fibrils, in spite of the random
reordering of amino acids in CDRs, gained additional support after the assessment of KW2
and KW3 binding properties. I demonstrated that those two VHH domains show strong
binding affinity to Aβ40 fibrils (Figure 3.20). Furthermore, they recognise neither freshly
dissolved Aβ peptide, nor oligomeric Aβ species, which is similar to B10. The affinity to
fibrils, and a simultaneous lack of interaction with oligomeric or disaggregated Aβ peptide,
qualifies KW2 and KW3 as conformation-specific antibodies. In addition, KW2AP and
KW3AP, have shown a very high specificity to a range of ‘B10-positive’ amyloid or amyloid-
like fibrils (Figure 4.5). The interaction of KW2AP was decreased with only two types of
Figure 4.5. Comparison of binding properties of KW2AP and KW3AP. KW2AP (grey bars) and
KW3AP (slate bars) staining level of different amyloid or amyloid-like fibrils. KW2AP and KW3AP
staining of Aβ40 fibrils was used as reference for full staining (red bar). Equal load of proteins on
the membrane was confirmed with Ponceau S staining; Ponceau S staining of Aβ40 fibrils was used
as reference for full staining (black bar); Ponceau S staining of the remaining fibrils was within 10%
range of the reference (data not shown). Experiment was carried out by Karin Wieligmann (HKI, Jena).
fibril (i.e., hSAA(1-12) all L, and full-length hSAA); KW3AP staining was reduced for the
full-length hSAA and mSAA fibrils. Remarkably, the fibrils that did not interact with B10AP
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(‘B10-negative’ fibrils) were also not recognised by KW2AP and KW3AP. The data presented
here indicate that the fibril recognition mechanism of B10, KW2, and KW3 is similar.
Striking binding similarity of KW2, KW3, and B10 can putatively be explained by the
presence of positively charged residues in the CDRs of those antibodies (Figure 3.21). Since
the crystal structures of KW2 and KW3 are not yet available, an ultimate explanation of their
binding mode cannot be provided. Nonetheless, the presence of multiple positively charged
amino acids, and the absence of negatively charged ones, appears to play a key role in the
binding mechanism.
The framework residues sometimes also participate in antigen binding (Kabat et al. 1992).
On one hand, this may be a tempting explanation for the common mechanism of binding of
VHHs with fibrils; however, it was not confirmed by the crystal structure of B10. On the other
hand, this possibility cannot be completely excluded, since the binding region of B10 might
undergo rearrangements upon coupling with fibrils.
Given the similarity of B10, KW2, and KW3 binding sites, as well as the resemblance of
the recognition pattern of amyloid fibrils, I conclude that the unique VHH framework (Habicht
2002), in combination with a strong cationic binding site, may constitute the functional core
for binding of amyloid fibrils by these domains.
4.2.5 Understanding the recognition mechanism of amyloid fibrils
The fact that B10, KW2 and KW3 bind the same fibrils underlines the role of positively
charged residues in fibril recognition. The design of VHH, with its unique framework,
enables the construction of antibodies with flexible binding sites and multi-ligand specificity.
Moreover, the mechanism of B10 binding proposed here is an indirect source of information
about surface and structure of fibrils. The highly ordered β-sheet core, common to all fibrils,
is insufficient to explain their discrete interaction with ligands; therefore studying the structure
of fibrils requires a custom approach that would provide detailed information about their
surface. According to structural models, the mid-region and C-terminal end of Aβ are buried
in the hydrophobic core of β-sheet (Soreghan et al. 1994), making them inaccessible for
antibodies. N-terminal specific antibodies, described by Gardberg et al. (2007), bind to fibrils
by taking advantage of the unstructured N-fragment of the Aβ polypeptide. However, their
sequence specificity does not facilitate selective Aβ species recognition. Hence, N-terminal
specific antibodies cannot discern between Aβ conformers. B10 might be able to distinguish
several amyloid pathologies, which are otherwise difficult, or altogether impossible, to
diagnose with other amyloid ligands.
Several mechanisms of antibody clearance of Aβ have been proposed. These include the
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peripheral sink hypothesis (DeMattos et al. 2001), direct resolution of Aβ (Solomon et al.
1997), and microglia-mediated Aβ clearance mechanisms (Istrin et al. 2006). It remains to
be seen which of these categories contain the recognition mechanism of B10. Antibody-
mediated clearance of amyloid aggregates might depend on multiple mechanisms. For
instance, the ability of B10 to stabilise protofibrils renders them more susceptible to direct
resolution, or to proteolytic degradation via microglia activation (Habicht et al. 2007). The
understanding of the mechanisms governing the binding of antibodies to amyloid aggregates
is crucial for designing effective therapeutic solutions or diagnostic reagents. Based on the
data accumulated here, several conclusions can be drawn regarding the fibril-specific modus
operandi of VHH antibody domains:
• B10 binding is mediated by electrostatic interactions, and requires surface-exposed
negatively charged groups on Aβ40 fibrils
• The shape of the B10 binding site restricts the recognition of fibrils containing flat
surfaces
• B10 binding to fibrils mirrors the pattern recognition mechanism of RAGE
• The relative arrangement of positively charged amino acids within the CDRs of B10
does not affect the recognition of fibrils
• The mechanism of fibril recognition by KW2 and KW3 antibody fragments is probably
the same as in B10
To the best of my knowledge, the data presented here for the first time elucidate the detailed
mechanism of recognition of different Aβ40 fibril-specific antibody domains. This mecha-
nism involves both electrostatic forces and surface complementarity.
4.3 Conformational recognition of the Aβ oligomers by KW1
In course of my research project, I assessed biophisically the KW1 antibody domain,
generated by phage display selection. The properties of KW1 include specificity to selected
Aβ40 conformers. Owing to these properties, KW1 is able to recognise certain oligomer
structures. In the following sections, I will discuss these properties in greater detail and
compare KW1 with other amyloid binders.
4.3.1 Implications of conformational specificity of KW1 VHH to Aβ oligomers
As established with SPR and ELISA, KW1 shows selective specificity for certain types of
Aβ conformers (Morgado et al. 2012). KW1 is able to discriminate specific Aβ40 oligomers
from fibrils and disaggregated peptides. Hence, KW1 qualifies as a conformation-specific
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antibody fragment. It differs from previously described B10 antibody fragment - specific
only for fibrillar Aβ states, as well as from sequence-specific binders, e.g. the mouse
monoclonal 6E10 antibody. The sequence-specific antibodies recognise several different Aβ
conformations derived from the same polypeptide chain (Vasilevko et al. 2007).
It has recently been demonstrated that incubation of the Aβ peptide in the presence of
KW1AP does not prevent formation of ThT-positive structures (Morgado et al. 2012). Yet, the
resulting aggregates did not have a typical fibrillar morphology. This suggests that the binding
of KW1 does not stabilise the oligomeric state. Instead, it may cause a certain conformational
transition of Aβ, which would prevent the assembly of Aβ into mature fibrils. B10AP displays
similar inhibitory activities of fibril formation; it also blocks Aβ assembly, but at a later step
than KW1AP; B10AP binds to protofibrils and promotes their accumulation (Habicht et al.
2007).
LTP measurements revealed that KW1AP-positive oligomers are synaptotoxic and lead
to neuronal impairment in living brain tissue (Morgado et al. 2012). Importantly, KW1AP
was shown to completely reverse oligomer-induced neuronal dysfunctions. Other monoclonal
antibodies, raised against the N-terminal part of Aβ, show the ability to disassemble Aβ
fibrils (Solomon et al. 1996). KW1AP displays a different mode of action. The result of
the incubation of KW1AP with pre-formed amyloid fibrils, and the absence of Aβ40 in
the supernatant, indicated that KW1AP was unable to disaggregate fibrils. The presence
of KW1AP mainly in the supernatant proved that the KW1AP epitope was not presented
on mature Aβ40 fibrils (Figure 3.24). This finding indicates that KW1 does not react with
already existing amyloid deposits, and points to its potential use as a selective marker specific
for toxic soluble intermediates.
The epitope study performed during the 24 h incubation of the Aβ peptide provided a
better understanding of the nature of KW1 recognition. The aggregation kinetics of Aβ,
monitored with ThT, had two distinctive phases: a well-resolved lag phase with formation
of nuclei, followed by a growth phase with elongation of Aβ fibrils (Figure 3.25). This
aggregation mode is well-established, and consistent with previous reports (Harper and
Lansbury 1997, Chiti et al. 2003). The KW1AP staining pattern suggests that the epitope
of KW1AP occurs early in the Aβ aggregation and is present over the whole incubation time
(Figure 3.27). This notion, however, is not supported by the TEM images prepared during the
Aβ aggregation: the oligomer-like spherical structures were not observed (Figure 3.26). On
the other hand, the oligomers were difficult to capture under semi-physiological conditions.
The transient character of oligomers was a possible reason for the lack of spherical species on
the TEM micrographs. An alternative explanation could be that spherical oligomeric species,
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which are a natural target for KW1AP, were formed and stabilised in HFIP. In the HFIP
solution, the oligomers took on a particular morphology (Figure 3.22). Hence, oligomers
with such morphology need not necessarily appear on the Aβ aggregation pathway.
The results of the 24 h incubation merely demonstrated that KW1AP recognises a certain
epitope, which occurs during the Aβ aggregation pathway, as indicated by the 70% staining
of KW1AP. The fact that KW1AP also binds spherical, HFIP-stabilised oligomers, confirms
that I managed to stabilise an oligomeric conformation, which transiently appears during Aβ
aggregation into fibrils.
4.3.2 KW1 specificity in relation to the structure of oligomers
As part of my research project I attempted to assess the specificity of KW1, and to
understand the mechanisms governing the recognition of oligomers by KW1. I examined
several factors potentially influencing this interaction.
I tested binding of KW1AP to several soluble variants of Aβ conformers. Oligomers
derived from the Aβ42 peptide, as well as oligomers originating from non-Aβ sequences,
were not recognised by KW1AP (Figure 3.30). Much to our surprise, not all of the Aβ40-
derived oligomers reacted with KW1AP. KW1AP was specific only to preparations I and II;
reaction with preparation III of Aβ40 oligomers was not observed. Accumulated data indicate
that the studied Aβ40 conformers display different structural epitopes (Figure 3.30a). These
results suggest that Aβ oligomers, even those derived from the same polypeptide chain, are
structurally polymorphic. Owing to its heterogeneity and transient character, the structure
of Aβ oligomers is still not fully elucidated. Initially, oligomers were reported to contain a
considerable amount of fibril-like, parallel β-sheet structure (Chimon et al. 2007). However
Habicht et al. (2007), using FTIR and far-UV circular dichroism, found that the β-sheet
structure of Aβ40 oligomers is primarily antiparallel. This was further supported by Ahmed
et al. (2010), who showed that oligomers are rich in β-sheet, but it is organised in a different
manner to the parallel, in-register, cross-β structure of Aβ fibril. Antiparallel organisation of
the β-strands in Aβ oligomers was also confirmed in several other studies (Eckert et al. 2008,
Cerf et al. 2009). The Glabe group proposed a recognition mechanism based on the interaction
of an antibody with the antiparallel structure of Aβ oligomers (Kayed et al. 2003, 2010).
Kayed et al. (2003) also suggested that oligomers recognised by the A11 antibody share a
common structure and a common mechanism of toxicity. Given the antiparallel structure of
many studied Aβ oligomers, the recognition mechanism proposed by the Glabe group may
hold true. Structural investigations of other, non-Aβ derived oligomers, i.e., ones obtained
from β2-microglobulin or PrP(82–146) peptide, revealed that they also possess the antiparallel
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β-sheet structure (Fabian et al. 2008, Natalello et al. 2008).
To determine whether the presence of antiparallel structure on oligomers explains its
interaction with KW1 antibody fragment, I investigated the secondary structure of several
oligomeric preparations with ATR-FTIR. From the obtained infrared spectra, I conclude that
the presence of an antiparallel β-sheet structure on oligomers does not alone determine the
interaction with KW1AP. FTIR measurements revealed an antiparallel structure of Aβ40
oligomers, namely preparation I (present study) and preparation III (Sarroukh et al. 2010);
preparation II was shown to possess a parallel β-sheet structure. Interestingly, KW1AP
interacted only with preparation I and II, but not with preparation III of Aβ40 oligomers.
Furthermore, I found that there exist more oligomers which do not interact with KW1AP,
despite their proposed antiparallel structure; these include preparation I and II of Aβ42
(antiparallel structure established in this study), preparation III of Aβ42 (Cerf et al. 2009)
and preparation IV of Aβ42 (Eckert et al. 2008). These results point out that in Aβ oligomers,
the content of the antiparallel β-sheet structure alone is insufficient to define the KW1 epitope.
The elucidation of the mode of KW1 recognition of Aβ oligomers requires further studies.
The narrow binding spectrum of KW1 is peculiar among oligomeric binders. For instance,
polyclonal antibody A11 binds to a whole spectrum of oligomers derived from different
preparations, including ADDLs, HMW oligomers, annular protofibrils, as well as non-Aβ
oligomers like calcitonin or α-synuclein (Kayed et al. 2003, 2010). Selective specificity of
KW1 is also distinct from previously described B10 antibody fragment, which binds to a broad
range of amyloid fibrils (Haupt et al. 2011a). However, the data presented here for KW1 are
in agreement with the finding of Lafaye et al. (2009): V31-1, an oligomer-specific VHH, is
conformationally specific only to LMW Aβ oligomers; it does not react with oligomers of
other amyloidogenic polypeptides (Lafaye et al. 2009).
The finding of De Genst et al. (2006) could be a plausible explanation for the unique
epitope recognition by VHH domains. De Genst et al. (2006) showed that VHH fragments
often possess a convex paratope; they thus exhibit an unusual ability to recognise a unique
epitope, often hidden in cleft protein surfaces; such antigen pockets are inaccessible for
conventional antibodies. However, the analysis of the crystal structure of KW1 revealed
that its binding site cannot be involved in such binding mechanism (Morgado et al. 2012).
The CDRs of KW1 are devoid of a deep binding cavity, although they are surely more
concave than the flat surface of B10 CDRs. The CDRs of KW1 capture a molecule of
benzamidine, an aromatic substance, from the crystallisation buffer (Morgado et al. 2012).
Oligomeric residues comprising phenyl rings seemed likely to be part of the epitope of KW1,
but incubation of KW1 with 105 molar excess of benzamidine did not influence the affinity of
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KW1 to oligomers (Morgado et al. 2012). However, the KW1-positive oligomers demonstrate
hydrophobic surface properties; they strongly interact with the fluorescent dye ANS (Haupt
et al. 2012).
The crystal structure of KW1 (Figure 1.13) suggests that the binding mechanism is differ-
ent to that previously described in B10 (Haupt et al. 2011b). The lack of a strong electrostatic
surface potential of KW1, and the prevalence of hydrophobic residues in the binding region,
may indicate that recognition of oligomers by KW1 is governed by hydrophobic interactions
rather than by electrostatic interactions (as it is in B10; Haupt et al. 2011b).
Distinct recognition mechanisms of KW1 and B10 are reflected in different structural
properties of their ligands. Aβ oligomers lack the structural regularities typical for Aβ fibrils.
The oligomers display micelle-like, hydrophobic structures (Fändrich 2012). Furthermore,
the transient nature of oligomers might result in dynamic changes in their structure. The
character of the KW1-oligomer interaction appears to be more complex than B10 recognition
of the regular surface pattern of fibrils, based on electrostatic interactions; however, this will
require further studies.
4.4 Final remarks
The conformation-specific antibody fragments directed against Aβ oligomers and fibrils
constitute a powerful tool for basic research of Aβ. They discriminate between different
conformational states of Aβ and might be used as selective markers for certain amyloid
species. In depth analysis of the B10 antibody fragment led to the elucidation of the
recognition mechanism of Aβ fibrils. The proposed B10-fibril interaction mechanism depends
on the basic CDR residues of B10 and confirms the presence of the strong acidic surface
potential on many amyloid fibrils. The fact that B10 recognises many (but not all) amyloid
fibrils may make it a selective diagnostic marker for many amyloid pathological conditions.
KW1, like other oligomer-directed antibodies, may aid in the quantification of amyloid
aggregates, as well as help us understand how those aggregates form; KW1 may also facilitate
the standardisation of protocols for preparation of prefibrillar aggregates. An improved
understanding of the KW1 binding mechanism could indirectly provide insights into the
structure of Aβ aggregates. Resolving the structure of Aβ oligomers should facilitate the
design of target-directed therapeutic strategies. In the future, it may lead to the elimination
of toxic Aβ entities from the brains of AD patients. Elucidation of the binding mechanism
of KW1 will enable a better understanding of the structural complexity of prefibrillar Aβ
conformers. The KW1 antibody fragment, given its selective binding properties, might serve
88
DISCUSSION
as a precise diagnostic tool; it possesses the ability to discriminate certain Aβ conformational
states. Such a sensitive molecular device is necessary to separate the toxic Aβ aggregates
from harmless or inert ones.
The initial human clinical trial with the use of anti-Aβ antibodies was halted due to
severe side effects – 6% of the patients developed meningoencephalitis (Schenk 2002). VHH
antibodies might overcome such problems, since single chain variable fragments cause neither
meningoencephalitis, nor cerebral haemorrhages (Marín-Argany et al. 2011). Hence, VHH
antibodies are a promising alternative to classical immunotherapy. In addition, the small size
of the VHH enables better tissue penetration, and may facilitate the crossing of the blood-
brain barrier (Muruganandam et al. 2002, Jones et al. 2010). VHH domains selected from
synthetic libraries might prove to be cheaper and faster, but also more effective alternatives to
antibodies generated with animal immunisation.
The monoclonal character of the B10, KW1, KW2 and KW3 enables large-scale produc-
tion in E. coli cells and a fast purification system. Genetic availability of VHHs capacitates
construction of new molecular payloads (enzymes, toxins or radionucleotides) with enhanced
binding properties and desired functionality (Holliger and Hudson 2005).
Specific recognition of Aβ by small molecules underlies currently tested therapeutic
strategies against AD (Lee et al. 2009, Frisardi et al. 2010, Lemkul and Bevan 2010, Ladiwala
et al. 2011). In this context antibodies play a very important role. The unique features of
VHH domains make them an excellent tool for basic research to study delicate Aβ structure
and mechanism of aggregation. Due to their conformational specificity and unique properties,
VHH antibody fragments designed to target only selected amyloid aggregates have great
potential as robust diagnostic reagents, or as non-immunogenic therapeutics (Holliger and
Hudson 2005).
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SUMMARY
Summary
Aggregation of the Aβ peptide is believed to be the cause of neurodegeneration of the brain.
However, the process of Aβ aggregation, as well as the structure of the intermediate and
final Aβ conformers, is not fully understood. Fibrils are the final product of Aβ aggregation.
They possess a very regular cross-β structure. In contrast, Aβ intermediates i.e., oligomers
and protofibrils, take on spherical or curvilinear structures, respectively. Several studies have
indicated that Aβ oligomers possess a considerable β-sheet structure, organised in an anti-
parallel manner. Still, more detailed information about their structure is scarce.
It is not entirely clear to what extent particular Aβ conformers contribute to AD. Hence,
practically all known Aβ species are targeted therapeutically. The development of diagnostic
and therapeutical approaches to AD has caused an increasing interest in immunotherapy. So
far, several antibodies targeting Aβ conformers have been described, but the mechanism of
their action is still poorly understood.
In my dissertation, I describe several small VHH antibody domains, selected with the use
of a camelid antibody library. Those VHH antibody domains are conformationally-specific
to different Aβ conformers. B10, KW2, and KW3 antibody domains are specific to Aβ40
fibrils, while KW1 is specific to Aβ40 oligomers. Using various biophysical (e.g., electron
microscopy, surface plasmon resonance) and biochemical methods (e.g., enzyme-linked
immunosorbent assay, immunoblot), I assessed the molecular mechanism of the binding, and
the conformational specificity of particular VHH antibodies to their respective targets.
The recognition of Aβ40 by B10, KW2, and KW3 proceeds in a conformation-specific
manner; these antibodies bind fibrils, but they interact neither with Aβ oligomers, nor with
the disaggregated Aβ peptide. In addition to Aβ40 fibrils, B10 binds to a range of amyloid-
like fibrils. Still, some fibrils (e.g., PABPN1-(+7), Aβ(16–22) fibrils) are not recognised by
B10. B10 also fails to bind to β-sheet rich globular proteins (e.g. lysozyme, transthyretin), or
to bind intrinsically disordered peptides (e.g., glucagon, poly-L-lysine).
In-depth analysis of the B10 recognition mechanism of Aβ fibrils showed that it involves
electrostatic interactions, as well as complementarity of flat surfaces on the antibody and the
fibril. Hence, B10 binds to fibrils possessing the following properties: a regular cross-β sheet
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structure (responsible for the flat fibril surface), and a regular distribution of anionic surface
charges.
KW1 domain binds to Aβ40 oligomers, but neither to Aβ40 fibrils, nor to Aβ disag-
gregated peptide. Furthermore, KW1 interacts only with a certain type of Aβ40 oligomers,
depending on the conditions of the preparation. In contrast, oligomers derived either from
Aβ42, or from non-Aβ peptides are not recognised. None of the analysed features of
oligomers (i.e., polypeptide origin, morphological appearance, presence of parallel or anti-
parallel β-sheet structure) predisposes oligomers to act as a KW1 ligand. The recognition of
Aβ40 oligomers might be based on hydrophobic interactions, as suggested by the analysis of
the crystal structure of KW1.
Antibody domains described in this dissertation constitute an excellent tool for structural
research on amyloid aggregates. The mechanism of VHH antibody recognition proposed
here is based on ionic (B10-fibrils) and hydrophobic (KW1-oligomers) interactions, and
this indirectly provides information about the surface structure of particular Aβ aggregates.
Furthermore, the binders described here are capable of distinguishing between different con-
formational states of Aβ, and may therefore prove useful in an assessment of the pathological
relevance of Aβ. Being selective to various Aβ conformers, recombinantly available VHH
domains bear a substantial potential as therapeutic or diagnostic agents.
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Zusammenfassung
Die Aggregation des Aβ-Peptides wird als Ursache von neurodegenerativen Vorgängen im
Gehirn angesehen. Allerdings ist der Prozess der Aβ-Aggregation, sowie die Struktur der
dabei auftretenden Aggregate bislang nur unzureichend verstanden. Als Endprodukte der
Aggregation bilden sich faserförmige Aggregate, die als Amyloidfibrillen bezeichnet werden.
Diese zeichnen sich durch eine gekreuzte β-Faltblattstruktur aus. Dagegen weisen die Vor-
läuferstrukturen von Amyloidfibrillen, wie Oligomere und Protofibrillen, eine kugelförmige
oder unregelmässig gekrümmte Struktur auf. Einige strukturelle Untersuchungen deuten
darauf hin, dass Aβ-Oligomere einen erheblichen Anteil an antiparalleler β-Faltblattstruktur
aufweisen. Allerdings existieren so gut wie keine detaillierteren Strukturinformationen zu
diesen Aggregaten.
Bislang ist nicht vollständig geklärt, welche Rolle bestimmte Aβ-Aggregate für die
Alzheimer-Krankheit spielen. Daher sind praktisch alle bekannten Aβ-Aggregate Ziel
von therapeutischen Ansätzen. Insbesondere für die Entwicklung von diagnostischen und
therapeutischen Strategien für die Alzheimer-Krankeit spielen Antikörper eine zunehmend
wichtige Rolle. Eine Vielzahl von Antikörpern gegen verschiedene Aβ-Aggregate wurden
in der Vergangenheit veröffentlicht, allerdings sind deren molekulare Mechanismen bislang
kaum verstanden.
In meiner Dissertation charakterisiere ich verschiedene VHH-Antikörperdomänen, wel-
che aus einer kameliden Antikörperbibliothek selektiert wurden. Diese VHH-Domänen zeich-
nen sich durch eine konformationelle Spezifität für verschiedene Aβ-Aggregate aus. Während
die Antikörperdomänen B10, KW2 und KW3 spezifisch an Aβ-Fibrillen binden, inter-
agiert KW1 spezifisch mit Aβ-Oligomeren. Unter Verwendung verschiedener biophysikalis-
cher (z. B. Elektronenmikroskopie, Oberflächen-Plasmon-Resonanz-Spektroskopie) und bio-
chemischer Methoden (z. B. enzymgekoppelter Immunadsorptionstest, Immunblot) habe ich
den molekularen Mechanismus der Bindung und die konformationelle Spezifität der einzelnen
VHH-Antikörper untersucht.
Die Erkennung von Aβ40 durch B10, KW2 und KW3 beruht auf einem konformationsspe-
zifischen Mechanismus. Das heisst diese Antikörper erkennen spezifisch Aβ-Fibrillen, jedoch
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nicht Aβ-Oligomere oder das disaggregierte Peptid. Zusätzlich zu Aβ40-Fibrillen bindet B10
eine Vielzahl von Nicht-Aβ-Fibrillen. Allerdings gibt ea auch einige Fibrillen (z. B. PABPN1-
(+7)-Fibrillen, Aβ(16-22)-Fibrillen), an die B10 nicht bindet. Darüber hinaus zeigt B10
keine sigifikanten Interaktionen mit β-Faltblatt-reichen globulär gefalteten Proteinen (z. B.
Lysozym, Transthyretin) oder intrinsisch ungefalteten Polypeptidketten (z. B. Glukagon,
Poly-L-Lysin).
Eine detaillierte Analyse des Bindungsmechanismus von B10 an Fibrillen zeigte, dass
elektrostatische Wechselwirkungen, sowie zueinander komplementäre flache Oberflächen
entscheidend für die Interaktion sind. Daraus ergibt sich, dass von B10 erkannte Fibrillen die
folgenden Eigenschaften aufweisen: eine regelmässige gekreuzte β-Faltblattstruktur, welche
verantwortlich für eine relativ flache Fibrillenoberfläche ist, und eine regelmässige Verteilung
von anionischen Oberflächenladungen.
KW1 bindet spezifisch an Aβ40-Oligomere, aber nicht an Aβ40-Fibrillen oder an disagg-
regiertes Aβ40-Peptid. Des Weiteren interagiert KW1, in Abhängigkeit von den jeweiligen
Herstellungsbedingungen der Oligomere, nur mit bestimmten Typen von Aβ40-Oligomeren.
Dagegen werden Oligomere des Aβ42-Peptides, als auch Oligomere von anderen Polypep-
tidketten nicht durch KW1 erkannt. Diese Spezifität lässt sich durch keines der unter-
suchten Merkmale der Oligomere (z. B. Polypeptidsequenz, morphologische Erscheinung,
β-Faltblatt-Organisation) erklären. Allerdings deutet die Analyse der Kristallstruktur von
KW1 darauf hin, dass die Erkennung von Aβ40-Oligomeren auf hydrophoben Interaktionen
basiert.
Die in dieser Dissertation beschriebenen Antikörperdomänen stellen hervorragendeWerk-
zeuge für die strukturelle Untersuchung von Amyloidaggregaten dar. Die hier vorgeschlage-
nen Erkennungsmechanismen der VHH-Antikörper, basierend auf ionischen (B10-Fibrillen)
oder hydrophoben (KW1-Oligomere) Wechselwirkungen, liefern indirekt Informationen über
die Oberflächenstruktur der jeweiligen Aggregate. Des Weiteren sind die beschriebenen
Antikörper in der Lage verschiedene konformationelle Zustände des Aβ-Peptides zu unter-
scheiden. Dadurch könnten die Antikörper nützlich für die Untersuchung der pathologischen
Eigenschaften von Aβ sein. Darüber hinaus besitzen rekombinante VHH-Domänen durch die
selektive Erkennung von verschiedenen Aβ-Aggregaten ein vielversprechendes Potenzial als
therapeutische oder diagnostische Werkzeuge.
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Abbreviations
3D Three-dimensional
Aβ amyloid β peptide
AβPP β-amyloid precursor protein
AD Alzheimer’s disease
ADDL Aβ-derived diffusible ligand
AFM Atomic force microscopy
ANS 1-anilino-8-naphthalene sulfonate
AP Alkaline phosphatase
ATR-FTIR Attenuated total reflectance Fourier transform infrared spectroscopy
BSA Bovine serum albumin
CD Circular dichroism
CDR Complementarity determining region
CNS Central nervous system
CR Congo red
cryo-EM Cryo-electron microscopy
DMSO Dimethyl sulfoxide
ELISA Enzyme-linked immunosorbent assay
EM Electron microscopy
HCAb Camelid heavy chain antibodies
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol
HMW High molecular weight
HRP Horseradish peroxidase
IEC Ion exchange chromatography
Ig Immunoglobulin
IMAC Immobilised metal ion affinity chromatography
IPTG Isopropyl β-D-1-thiogalactopyranoside
IUPC Intrinsically unfolded polypeptide chain
aKD Apparent dissociation constant
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LMW Low molecular weight
LTP Long-term potentiation
NMR Nuclear magnetic resonance
OD Optical density
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PS1 Presenilin 1
PS2 Presenilin 2
PVDF Polyvinylidene fluoride membrane
RAGE Receptors for advanced glycation end products
RPC Reversed phase chromatography
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SD Standard deviation
SEC Size exclusion chromatography
SPR Surface plasmon resonance
ssNMR Solid state nuclear magnetic resonance
TBS Tris-buffered saline
TEM Transmission electron microscopy
TFA Trifluoroacetic acid
TFE Trifluoroethanol
ThT Thioflavin T
VHH Camelid variable heavy chain domain
WB Western blot
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